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The development and optimization of anti-viral screening methods are essential to develop 
newer more effective, treatments against HIV.  
 
The XTT method is a widely described method for antiviral screening. Both continuous HIV-
infected cells and experimentally infected T-cells have been used in the XTT assay. We 
compared these methods to screen several plant-derived extracts for cytotoxicity. Several 
considerations were taken into account when performing these tests (effect of media, solvents 
and plant enymes). Experiments were performed to investigate these effects. In addition, p24 
and viral load quantification were compared as antiviral screening methods. 
 
The study showed that several modifications were necessary when performing the XTT assay 
on plant extracts, due to the effect of media, solvents and plant enymes. The XTT assays and 
p24 assays performed using experimentally infected cells are far more specific than those 
using chronically infected cells. The use of viral loads as an antiviral screening method 










Chapter 1: Review of Literature 
1.1 Comments on the HIV pandemic 
 
The human immunodeficiency virus (HIV), the aetiological agent of the acquired 
immunodeficiency syndrome (AIDS), is responsible for one of the worst pandemics to affect 
mankind. UNAIDS has estimated that 40.3 million people globally, and 5.5 million people in 
South Africa were living with HIV in 2005. According to the National HIV and Syphilis 
Prevalence Survey (2005), approximately 39.1% of antenatal attendees in KwaZulu-Natal 
were HIV positive. An estimated 2.8 million people worldwide died of the disease in 2005 
alone, of which 2 million deaths occurred in sub-Saharan Africa (UNAIDS).  
 
These statistics illustrate the global burden of the HIV pandemic and in particular its 
devastating effects in sub-Saharan Africa. The search for a preventative or therapeutic vaccine 
against HIV is the focus of intense research and monetary investment. Antiretroviral therapy 
has transformed a life threatening illness into a chronic manageable condition for individuals 
who have access to treatment. However, there is at present no successful vaccine or curative 







1.2 Viral targets 
 
The main targets of HIV-1 are CD4+ T cells, although other cells such as monocytes and 
macrophages are susceptible, since these cells also possess the CD4 cell surface antigen. This 
was explained by the discovery that the viral-envelope glycoprotein, gp 120, has a high 
affinity for the CD4 receptor (Dalgleish et al., 1984). However, experiments using 
mammalian cells transfected with the human CD4 gene alone did not exhibit susceptibility to 
HIV infection, leading to the conclusion that CD4 was not the sole receptor responsible for 
HIV infection of cells. Years later, a group of cell-surface chemokine receptors was 
identified, two of which are significantly relevant to HIV infection, namely CXCR4, 
originally called Fusin,  (Feng et al., 1996) and CCR5 (Dragic et al., 1996). CXCR4 is 
designated as the co-receptor for syncytium-inducing strains of HIV, which appear late in 
infection, while CCR5 acts as the co-receptor for the non-syncytium-inducing primary strains 
of HIV and SIV, also known as macrophage tropic viruses (Deng et al., 1996; Dragic et al., 
1996). Dendritic cells are moderately susceptible to HIV since they express low levels of 
CD4+, CCR5 and CXCR4 (Patterson et al, 2001; Sol-Foulon et al. 2002). Stebbing et al., 
(2004) showed that macrophages, having engulfed HIV infected lymphocytes, are fairly 
resistant to cytolytic effects and could act as a reservoir for the virus, while viral DNA has 
been shown to persist in natural killer cells up to 2 years after effective HAART (Velentin et 








Once the virion has bound to the cell receptors, conformational change in the gp120 occurs, 
resulting in the fusion of the virion envelope with the cell membrane aided by the fusion 
protein gp41 (Haseltine et al., 1990). Entry is further facilitated by co-receptors CCR5 or 
CXCR4 chemokine receptors as a result of interaction between the viral gp120 and these 
receptors (Khan 1990, Lennette 1995).  
 
Within the cell, the uncoated virion undergoes reverse transcription, resulting in the 
production of a double-stranded DNA copy (cDNA) of the viral RNA. This viral cDNA is 
transported to the nucleus where it is integrated into the host genome by the viral enzyme 
integrase. The viral DNA is flanked by two long terminal repeats which are sequences 
essential for the transcription of the provirus (Lennette et al., 1995; Lennette et al., 1999). 
Viral mRNA is then transported out of the nucleus into the cytoplasm where it is translated. 
The genomic RNA along with translated viral proteins are assembled into virions that bud at 
the cell membrane. HIV protease cleaves the Gag-Pol proteins into their constituents and, in 
doing so, completes the maturation process of budding virions. As each virion is expelled 
from the host cell, it takes with it a lipid bilayer envelope from the host cell membrane 






Figure 1: Early and late events in HIV-1 replication (Nisole and Saib, 2004) 
1.4 Viral Phenotypes  
Table 1: HIV isolate attributes 
 X4 R5 
Co-receptor CXCR4 CCR5 
Syncytia SI NSI 
Replication Rapid Slow 
Infection Late Early 
Tropism T-tropic M-tropic 
 
Isolates of HIV vary in their tropism, replication capacity, co-receptor usage, stage of disease 
progression and the ability to form syncytia (Regoes et al, 2005). These attributes need should 
be considered when using these isolates in cell based assays e.g. X4 HIV-1 isolates may 
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1.5 Progression of infection 
 
The virus reaches the regional lymph nodes where extensive replication occurs. This is 
followed by a rapid rise in the viral load and dissemination of virus to other parts of the body. 
Only about 2% of the total viral load exists in the blood while approximately 98% exists in 
the tissues such as those of the central nervous system and in tissue macrophages (Lennette et 
al., 1999). The initial viraemia can exceed several million copies per millilitre of blood. The 
immune system reduces viral replication to a steady state by initiating a virus-specific 
immune response. CD8 lymphocytes (cytotoxic-T cells) play a crucial role by inducing cell 
lysis of infected cells. A patient who has a high initial viral load is a more likely to progress 
rapidly to AIDS and death. 
 
Seroconversion occurs between one week to three months (Pantaleo et al., 1993) after 
exposure and manifests as fever, diarrhoea, lymphadenopathy and a macular papular rash 
(Acute Seroconversion Illness). These symptoms generally last up to four weeks. This is 
followed by an asymptomatic phase that may persist up to 10 years or longer. Finally, the 
symptomatic phase results, correlating with a decline in immune competence and the 
appearance of secondary infections. Viral load increases, CD4 cell count drops and 
opportunistic infections set in. At this stage, the transition from HIV infection to AIDS is 
complete, and in most cases the patient will die within 2 to 10 years of the onset of infection.    
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The great concern with HIV infection is that, as the virus replicates, mutations are induced as 
well as adaptations to the environment (Douglas, 1996). This occurs because the virus reverse 
transcriptase lacks proofreading mechanisms and is thus more error-prone than DNA 
polymerases (Hinuma et al, 1982). However, this results in the production of at least one base 
change at each round of replication, and with an estimated 10
10
 virions produced each day 
from a genome of 10
5 
bases, at least one mutation at each nucleotide is produced each day. As 
a result enormous amounts of continuously generated variants, each with its own selective 
advantage are incorporated in the infected individual. The large numbers of virions produced 
compensate for the proportion of non-functional virions. Thus, an HIV positive individual 
may be infected with a population of HIV strains, each with varying genotypic and 
phenotypic characteristics, known as “quasispecies”. 
1.6 Available Treatment  
 
Treatment includes the use of antiretrovirals that either inhibits the viral enzymes reverse 
transcriptase and protease or blocks the fusion of the virion to the CD4+ target cell. Treatment 
has been shown to reduce the amount of HIV in blood (Lennette et al., 1999). Several types of 
antiretroviral drugs are available for the treatment of HIV (Table 1). Five classes are 
discussed: 
 
1. Nucleoside analogue reverse transcriptase inhibitors (NRTIs) 
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 The NRTIs were one of the first drug types used in the treatment of HIV infection (Lennette 
et al., 1995; Potter et al., 2004). Their function is to intercept the synthesis of DNA by 
inhibiting the viral enzyme reverse transcriptase, which is responsible for copying the viral 
RNA into DNA in an infected cell. Since nucleoside analogues are mono-phosphorylated, two 
additional phosphorylations are required to achieve triphosphorylation before these analogues 
are able to serve their role as active, DNA synthesis inhibitors (Cohen and Fauci, 2001; De 
Clercq, 1987). The phosphorylated NRTIs are mistaken for natural nucleosides by the reverse 
transcriptase enzyme, and are incorporated into the viral cDNA chain. However, when NRTIs 
are incorporated into a DNA strand during synthesis, further nucleoside addition is prevented, 
due to the absence of a 3’ OH group. This results in chain termination and the production of 
an incomplete copy of DNA. 
 
 
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)  
  
The NNRTIs impede viral DNA synthesis by inhibiting reverse transcriptase. Unlike the 
NRTIs, however, which bind to the active site of reverse transcriptase, the NNRTIs bind 
adjacent to the active site, and prevent its interaction with natural nucleotides by 
stereochemical interference.  This occurs since the shape of the enzyme is changed preventing 
its normal activity (Lachman 1990). 
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3. Protease Inhibitors (PIs)  
 
 Proteases are digestive enzymes contained in living cells as well as in viruses and are 
responsible for cutting up and processing proteins into their functional forms. The HIV 
protease cleaves the gag-pol polyprotein into functional units. Protease inhibitors bind to the 
HIV protease preventing the enzyme from correctly processing the viral proteins into their 
functional forms (Potter et al., 2004). These viral protein particles are immature, and the 
resulting virion is therefore non-infectious. The PI drugs in use are generally peptide-
mimicking compounds which greatly resemble the natural substrate of HIV protease. These 
drugs are also able to bind more tightly to the protease than the natural substrate.  
4. Fusion Inhibitors  
 
Drugs of this class target the HIV envelope protein gp41, which is involved in viral entry into 
new cells. These drugs block the interactions between regions of the gp41 molecule with the 
target cell membranes therefore preventing fusion (Potter et al., 2004). Fusion inhibitors 
interfere with the conformational change of the envelope molecule, required for virus entry 
into target cells (Lennette et al., 1995; Lennette et al., 1999).  
 
5. Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)  
 
The NtRTIs are a new generation of drugs that have a similar mechanism of action as NRTIs, 
but are monophosphorylated. The only approved NtRTI at this stage is Tenofovir, which is 
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metabolised intracellularly to its active form, Tenofovir diphosphate, in order to facilitate 
DNA chain termination. Tenofovir has a better pharmacokinetic, toxicity and resistance 
profile than NRTIs (Lyseng-Williamson et al., 2005).  
1.7 AZT (3’-azido-2’,3’-dideoxythymidine)  
 
This Nucleoside Reverse Transcriptase Inhibitor was first synthesised by Horowitz et al. 
(1964) and modified by Lin and Prusoff in 1978 (Mitsuya et al., 1985). Ostertag et al. (1974) 
first reported the activity against the Friend retrovirus and showed that AZT in its tri-
phosphorylated form results in chain termination (De Clercq et al., 1987). 
 
                                      
Figure 2: AZT structure (De Clercq, 2001) 
The azido group contributes to the lipophillic nature of the compound, allowing it to easily 
diffuse across cell membranes and the blood-brain barrier (Balzarini et al., 1999). Cellular 
thymidine kinase converts AZT to the 5’-mono-, di- and tri-phosphate forms (Furman et al., 
1986), which have the ability to inhibit HIV reverse transcriptase by competing with 
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endogenous nucleosides for incorporation into the DNA chain generated by the reverse 
transcription of HIV RNA. Chain termination is due to the absence of a 3’-hydroxyl group in 
AZT. The 3’-hydroxyl group allows for the attachment of nucleotides to the growing DNA 
chain. 
Table 2: Classes of licensed HIV-1 antiretroviral drugs 






Zidovudine    (AZT) 
Didanosine    (ddI) 
Zalcitabine    (ddC) 
Stavudine      (d4T) 
Lamivudine  (3TC) 








synthesis of viral 
DNA/ causes chain 
termination to 






Tenofovir       (TFV) Reverse 
Transcriptase 
• As for NRTIs 








Nevirapine     (NVP) 
Delaviridine  (DLV) 
Efavirenz       (EFV) 
Reverse 
Transcriptase 
• Not phosphorylated 
• Non-competitive 
inhibition of viral 
DNA synthesis 





Saquinavir     (SQV) 
Indinavir        (IDV) 
Ritonavir       (RTV) 
Nelfinavir      (NFV) 
Amprenavir   (APV) 
Lopinavir       (LPV) 
Ataznavir      (ATV) 
Darunavir(TMC114) 
Protease • Binds to active site 










The introduction of Highly Active Antiretroviral Therapy (HAART) results in a reduction in 
plasma viral load to below detection limits (Potter et al., 2004) and has extended the 
asymptomatic phase of infection, thereby increasing the quality of life for many infected 
individuals (LaBranche et al., 2001). HAART, or triple therapy, which typically includes a 
minimum of two NRTIs and a PI or a NNRTI, has dramatically changed the prognosis of 
HIV-infected individuals in the developed world (Pallella et al.. 1998). However, given that 
HIV cannot be eradicated, most patients select drug resistant strains over time and need a 
change in their treatment combination. The accumulation of multiple resistance mutations is a 
major obstacle to the long-term control of viral replication (Shafer et al., 1998). This fact 
validates the continuous need for new drugs, particularly compounds belonging to new classes 
which target different steps of the HIV replication cycle, and lack cross-resistance with 
current anti-retrovirals (Poveda et al., 2005). 
 
1.9 Problems with currently available drugs 
 
Toxicity, poor adherence and development of resistance are obstacles to the success of 






Various factors influence the incidence of adverse effects associated with current 
antiretroviral drugs including the ethnic origin of the patient, nutritional status, problems with 
adherence, drug interactions and the use of concurrent medications. Side effects may be 
minor, severe or even life-threatening (Table 2) and may influence quality of life, adherence 
and development of resistance. 
 
Peripheral neuropathy occurs in patients taking d4T in combination with isoniazid, an anti-TB 
drug. This type of drug combination is common in HIV infected patients since these 
individuals are susceptible to opportunistic infection such as tuberculosis. Continued 
treatment, in such instances, impairs the patient’s ability to function, thus reducing his/her 
quality of life. 
In some cases, side effects may escalate to life threatening conditions such as severe mucosal 
and skin lesions (e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis) 
(Colebunders et al., 2004). These, in addition to other conditions such as severe 
hepatotoxicity and lactic acidosis, require treatment interruption. 
 
In the case of pregnancy, certain drugs such as Efavirenz cannot be administered as a result of 
its teratogenicity (SUSTIVA Package Insert). 
 
Mitochondrial toxicity, lipodystrophy, dyslipidaemia and hyperglycemia are adverse effects 
of antiretroviral therapy, collectively known as Syndrome X. NRTI inhibition of 
mitochondrial DNA polymerase gamma leads to mitochondrial toxicity by an impairment in 
the synthesis of the mitochondrial enzymes required in the generation of ATP by oxidative 
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phosphorylation (Moyle, 2000; Feng et al., 2001; Potter et al., 2004). Lactic acidosis results, 
due to elevated plasma lactate levels (Birkus et al., 2002). NRTI and PI use leads to 
lipodystrophy, characterised by peripheral lipoatrophy of the limbs, buttocks and face, 
accompanied by an accumulation of fat around the abdomen and trunk. Lactic acidaemia, 
insulin resistance, hypertriglyceridaemia and hypercholesterolaemia are the metabolic features 
associated with lipodystrophy (Chen et al., 2002). 
 
As a result, patients on antiretroviral therapy require constant laboratory and clinical 
monitoring and specialised medical care to minimise the risks and adverse effects associated 
with treatment. 
 
Patients also may experience side effects such as nausea or vomiting which contributes to 
poor adherence to drug regimens. This, compounded by issues such as poor drug penetration 
into certain tissues, low levels of viral replication in cellular reservoirs, high pill burden and 
complex regimens are also significant obstacles to successful antiretroviral treatment.  
 
 
1.9.2 Development of Resistance 
 
Suboptimal treatment with antiretroviral drugs can result in the selection of HIV variants with 
resistance to NRTIs, NNRTIs or PIs which may lead to treatment failure, disease progression 
and AIDS. The emergence of resistance can be attributed to the genetic variability of HIV 
arising from the high viral replication and mutation rates, viral recombination, poor adherence 
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and drug selective pressures (Table 2). 
 
Genetic variability manifests in infected individuals as a complex mixture of heterogenous 
strains of HIV known as “quasispecies”. These quasispecies compete amongst themselves to 
survive and propagate and this process is determined by intra-host factors. The dominant 
strains are those which have shown successful adaptation to this environment. However this 
process, while advantageous to the virus, is a key determining factor in the emergence of drug 
resistant virus. The number of cases involving the transmission of resistant viruses to newly 
infected persons is also on the increase (Blower et al., 2001; Hecht et al., 1998).  
 
 
RNA viruses such as HIV have a mutation rate, due to the error-prone reverse transcriptase 
enzyme, which is 100 times higher than that of DNA viruses, bacteria as well as other 
eukaryotes (Mansky et al., 1995; Monno et al., 1999). Furthermore, HIV has a high turnover 
which is estimated to be 10
9
 virions per day (Potter et al, 2004). The combination of the high 
mutation rate and rapid viral turnover is also a key factor in the emergence of drug-resistant 
variants. 
Genetic recombination is a process that further contributes to resistance, particularly high-
level multi drug resistance (Moutouh et al., 1996; Wain-Hobson et al., 2003; Yusa et al., 
1997). Recombination is a strategy for viral rejuvenation and the generation of genetic 
diversity which may create a multiple drug resistant virus out of two single-drug resistant 
viruses (Moutouh et al., 1996; Kellam et al., 1995; Gu et al., 1995; Burke, 1997) and is likely 
to facilitate the evolution of viral stains displaying resistance to all anti-HIV-1 drugs. 
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Other factors influencing viral resistance include the selective pressures imposed by 
antiretroviral drugs, suboptimal pharmacokinetics, poor drug penetration, continued viral 
replication in cellular reservoirs and inadequate patient adherence (Larder, 2001; Potter et al., 
2004). 
 
Patients who fail therapy have minimal options for further clinical management. There 
therefore needs to be a strong focus on research into new drugs that could target other aspects 
of the HIV replication cycle giving rise to new classes of drugs, or new drugs in existing 












Table 3: The obstacles to successful HAART  
Obstacles to effective HAART Associated problems 
Factors influencing adherence  to  medication • Pill burden 
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 • Dietary requirements 
• Concurrent medication  
• Drug interactions and Side effects 
Side Effects Minor 
• Nausea, vomiting, dizziness 
Severe 
• Peripheral neuropathy 
• Lactic acidosis 
• Lipodystropy 
Life-threatening 
• Stevens-Johnson Syndrome 
• Hepatotoxicity 
Teratogenecity 
Development of Drug Resistance • High rate of viral replication 
• Viral genetic diversity 
• Viral recombination 
• High mutation rate 
• Drug selective pressures  
• Drug pharmacokinetics 
• Continued viral replication in 
reservoirs 
• Poor adherence 
 
1.10 New drugs and drug targets 
 
There is great urgency in the search for and development of new drugs that will be easily 
available to patients, well-tolerated without devastating side effects and with the potential to 
suppress viral strains which are already resistant to existing drugs. The challenges faced 
include issues of drug potency, pharmacokinetics and the ability of new drugs to “resist” 
resistance. 
With this in mind, new viral targets have been identified, providing new opportunities for 
drug discovery (Table 3). Many new drugs targeting HIV reverse transcriptase and protease as 
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well as the fusion process are in development (Table 3), with the hope of finding new options 




The envelope protein complex (Env) of HIV controls the mechanism of viral entry into cells 
(Chan and Kim, 1998). Env is composed of the transmembrane sub-unit gp41, which is made 
up of heptad repeat regions known as HR1 and HR2, and the surface sub-unit gp120, which is 
non-covalently associated with gp-41. The process of viral entry is initiated by the binding of 
the virion gp120 to the CD4 molecule on target cells, which induces a conformational change 
resulting in the secondary binding of gp120 to the co-receptor CXCR4 or CCR5, depending 
on the infecting virus strain (Lenette, 1995). The result is a shift from a non-fusional state to a 
fusional state (Poveda et al., 2005).  
 
 
This then triggers a conformational change in transmembrane gp41 resulting in the initiation 
of the fusion process. The N-terminus domain of gp41 becomes exposed and is inserted into 
the cellular membrane forming a fusion “pore”, thus allowing the fusion of the viral 
membrane with the target cell membrane. This results in the entry of the viral capsid into the 
cytoplasm (Weiss, 2003) 
 
In 1993 a synthetic peptide called DP-178 was designed with a similar amino acid sequence to 
HR2. Renamed, T-20 or Enfuvirtide (Wild et al., 1993) this drug mimics the HR2 region of 
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gp41 (Dietrich, 2001; Weiss, 2003) and became the first fusion inhibitor approved for clinical 
use.  In addition to the fusion inhibitors, other examples of entry inhibitors include the co-
receptor agonists such as bicyclams, which were initially postulated to have inhibitory effects 
on the viral uncoating process (De Clercq, 1995).  
 
It is evident that HIV entry is a complex process involving an array of protein interactions, 
each of which may be potential targets in the search for new drugs to treat HIV infection (Cos 
et al., 2004; Kilby and Eron, 2003; Poveda et al., 2005). 
 
1.10.2 Reverse Transcription 
 
Once the viral capsid has entered the cytoplasm, enzymes within the nucleoprotein complex 
are activated. The viral core undergoes progressive disassembly (Nisole and Saib, 2004), 
known as uncoating and the pre-integration complex is formed (Krogstad, 2003). This 
complex includes viral RNA, reverse transcriptase, integrase and protease, and other viral 
proteins required for the translocation of the viral DNA complex to the nucleus where the 
linear viral DNA copy is inserted into the host cell genome. The RNA molecules packaged 
within the pre-integration complex are reverse transcribed by reverse transcriptase into a 
double-stranded DNA molecule or cDNA (Telesnitsky and Goff, 1997).  
 
The HIV-1 reverse transcriptase controls three functions. These are the reverse transcription 
of viral RNA to DNA by the RNA-dependant DNA polymerase activity of reverse 
transcriptase, the degradation of the RNA template by RNAse-H activity and the duplication 
1919  
of the remaining DNA strand by DNA-dependant DNA polymerase activity.  
 
The viral reverse transcriptase is a unique target since the process of RNA-directed synthesis 
of DNA does not occur in uninfected cells. As a result, this enzyme has been and still is 
considered to be one of the foremost targets for new antiretroviral drugs in the NRTI, NNRTI 




On completion of the reverse transcription process, the pre-integration complex is transported 
through the nuclear pores into the nucleus where the double-stranded viral DNA (cDNA) is 
integrated into the host genome by the viral enzyme integrase (Cos et al., 2004; Potter et al., 
2005; Tang et al., 1999).  This occurs through the assembly, processing and subsequent strand 
transfer of the viral DNA complex (Condra et al., 2002). Integrase achieves these functions by 
first cleaving the last two nucleotides from the 3’-end of the linear viral DNA, which then 
covalently links to the host chromosomal DNA. Finally unfolding occurs and gaps are 
repaired by cellular enzymes (Krogstad, 2003; Middleton et al., 2004).  
Studies using integrase-negative mutants of HIV show the production of non-infectious virus 
particles illustrating that HIV integrase would be an attractive target for inhibition.  
 
1.10.4 Transcription and Protease Activity 
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The two long terminal repeats that flank the viral DNA are necessary for transcription. The 
trans-activator protein TAT levels increase after integration of the viral DNA into the host 
genome and further aids the process of transcription by stimulating the transcriptional activity 
of the long terminal repeats (Mann and Frankel, 1991).  
 
The viral mRNA is transported out of the nucleus into the cytoplasm, where translation 
occurs. The RNA transcripts, as well as translated viral proteins are assembled into virions 
that bud at the cell membrane. The HIV enzyme protease then becomes active, leading to the 
cleavage of the Gag and Gag-Pol polyproteins and the re-organisation of the viral core 
(Krogstad, 2003). This process ensures the budding of mature, infectious progeny virions. 
 
Studies using virus with mutations in the active site of HIV protease or the use of drugs which 
exert pharmacological inhibition of protease activity, produce immature, non-infectious 
progeny virions (Schatzel et al., 1991). 
 
 
The chemistry, enzymology and pharmacology of protease inhibition in general is well 
studied and this information has been applied specifically to the development of new and 
improved protease inhibitors that can be used against HIV. HIV protease is therefore an 
attractive target for the pharmaceutical industry. 
 
A novel class of drugs, the maturation inhibitors, prevents the formation of mature infectious 
virions and could be of great use in curbing the production of new virions. 
2121  
 
1.10.5 Assembly inhibitors 
 
The assembly and release of newly produced virions is mediated by the viral proteins GAG 
and VPU (Freed, 1998; Klimkait et al., 1990).  The potential therefore exists to discover and 
develop drugs that are able to bind to one of these viral proteins and therefore block the 
process of assembly or release. According to Condra et al., (2002) a tripeptide, Gly-Pro-Gly-
NH2 (GPG), currently under development, binds to HIV p24 capsid protein and possibly 
interferes with gag oligomerisation, thereby disrupting the assembly pathway.  
Once the details of such mechanisms are better understood, it would be possible to discover 
new drugs that work via this method and provide effective clinical results. 
 
1.10.6 Zinc-finger inhibitors 
 
Zinc fingers are a chain of amino acids found in the viral core nucleocapsid protein, which are 
involved in the packaging of viral RNA into new virions. This target could hold the potential 
for the discovery of a new class of antiretroviral drugs that prevent the production of mature, 
infectious virions. 
 
1.11 Enhanced Pharmacokinetics 
 
Another method of drug therapy involves combinations of drugs (Table 3). An example is 
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Kaletra, which is a combination of Lopinavir and Ritonavir. Combining drugs reduces 
the pill burden, promotes adherence and improves pharmacokinetics. Protease inhibitors such 
as lopinavir are metabolised into their inactive states by the cytochrome P450 system, mainly 
by the action of cyp3A4. Frequent dosing is required to maintain these drugs at therapeutic 
levels. Ritonavir, a component of Kaletra inhibits the cytochrome P450 system and thereby 
prevents the rapid clearance of Lopinavir, maintaining effective drug levels for a longer 
period of time.      
 
1.12 Other forms of therapy 
 
Other forms of therapy being investigated (Table 3) include immunomodulators, such as 
interleukin 2; therapeutic vaccines; interfering RNA (Novina et al., 2002), and gene therapy 








Table 4: Strategies for new therapy options 
 Target Examples 




• Nucleotide analogues –  tenofovir 













• NNRTIs – eg. TMC-120 and 
DPC082     
• Inhibitors – eg. Tipranavir (TPV), 
BMS 232632, DPC 681 and TMC 
126 
• Gp41 inhibitor – eg. T 1249  
















• Inhibitors of gp120 binding to 
CD4 - eg. PRO524  
• Inhibitors of  coreceptor CXCR4– 
eg. Bicyclam AMD 3100, ALX 
40-4C, T22, T134 and T140 
• Inhibitors of coreceptor CCR5 – 
eg, SCH-C, TAK 779, the anti-
CCR5 monoclonal antibody 
PRO440 and, SCH-D 
• Integrase inhibitors eg.  diketo 
acids as inhibitors of strand 
transfer 
• Inhibitors of gag  oligomerisation 
– eg,  GPG  
• Inhibitors of assembly and 













Other New therapy 
strategies 
• Immune therapy eg. Use of IL-2 
• Therapeutic vaccine 
• Interfering RNA 




1.13 The discovery and development of new drugs 
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Ideal antiviral drugs should be able to achieve clinically effective levels in patients, have an 
acceptable therapeutic index (which is the ratio of efficiency to toxicity) as well as have 
adequate distribution and penetration at the tissue level (Doniger et al., 2004). The antiviral 
should also feature characteristics such as favourable dosing as well as be easily stored and 
stable at room temperature. In addition, the antiviral should not readily select drug-resistant 
variants nor should it antagonise the activity of other antiretroviral treatments. But, most 
importantly, an effective antiviral should be easily available and affordable.  
 
Given the globally acknowledged demand for new antiretroviral drugs, sources of potential 
agents need to be identified and methods to optimise the testing of these agents need to be 
established. This process of drug discovery, from the initial preclinical testing of the potential 
agent to the later phases of clinical trials, is an expensive process which, on average, may take 
between 12 and fifteen years to bring the product to market. In order for novel drugs with 
potential antiretroviral activity to be investigated, these procedures need to be made more 
efficient and cost effective. 
 
1.13.1 Reverse pharmacology versus conventional pharmacology 
 
A rational or conventional approach to drug discovery is one that requires the use of screening 
models to test the products of drug design. 
When using the empirical or reverse pharmacology approach, screening models become the 
primary tools for new drug discovery. 
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In conventional pharmacology, molecular design plays a vital role in the “creation” of 
potential antiviral agents. This is based on the identification of a potential target and the use of 
medicinal chemistry in the design of a molecule which will have specific inhibitory effects on 
the target of choice e.g. several protease inhibitors were developed for clinical use by rational 
investigation of their structure-activity relationship with the HIV protease active site (Kempf 
et al., 1998). Various biochemical tests are used to elucidate the mechanism of action of the 
potential agent. 
 
In the context of antiviral screening, reverse pharmacology, as its name suggests, involves the 
screening of large numbers of potential agents in order to find a lead compound with an 
inhibitory effect on one or more targets. The focus lies on the identification of a lead 
compound, using various cell-based assays, rather than on isolating the viral target that is 
being affected and what mechanism of action is being employed. 
 
While this method has been criticized as being inefficient by some (Burns and Groopman, 
1987), reverse pharmacology has been shown to be the most successful drug discovery 
approach in various areas of pharmaceuticals, particularly in the discovery of clinically useful 
anticancer drugs (Boyd, 1988).  
 
The empirical screening process has a particular advantage when testing natural products for 
new antiviral leads. The initial testing of crude natural product extracts with indicators of 
potential antiviral activity generally leads to the extensive screening of the partially purified 
fractions of the extract. 
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Also, once a new lead compound of natural or synthetic origin has been identified through the 
empirical process, aspects of the rational method may eventually be employed to modify the 
compound structure in order to improve various characteristics, including solubility and 
stability. This process is known as “lead optimization” and occurs much later, after the 
empirical screening process has been successful in finding potential antiviral activity in vitro. 
The two processes of conventional and reverse pharmacology are therefore intimately linked, 
and this is further demonstrated by the fact that there is a constant emergence of new ideas for 
the design of new molecules for drug design or rational pharmacology, which emanates from 
the screening of potential agents using the empirical method. 
 
 
At present, a wealth of knowledge exists of the molecular biology of HIV and its effects on 
host cell targets. This alone provides new platforms for research into successful conventional 
pharmacology methods of drug design. However, reverse pharmacology has the benefit of 
large-scale screening of a plethora of natural and synthetic compounds, either completely 
novel, or previously investigated for other uses. 
Boyd (1988) has documented that many of the most important clinically used drugs, across all 
pharmaceutical classes, have their origins as natural products that have been discovered 
through the empirical screening process. 
Examples of commonly available drugs that have been derived from natural sources include 
aspirin, penicillin, digoxin and morphine. Of the world’s twenty five best selling 




With 21st century technology and resources at our disposal, the most prudent approach would 
be the complementary and synergistic use of both reverse and conventional pharmacological 
methods in our search for novel HIV drugs. 
 
1.13.2 Natural products as potential anti-HIV agents 
 
An array of natural products has been found to show inhibition of specific proteins and 
enzymes that are crucial to the HIV replication cycle (Notka et al., 2004). As reviewed by Cos 
et al., (2004), De Clercq (2000) and Vlietinck et al., (1998) some of these natural agents 
display efficient intervention with the processes of virus binding to target cells, reverse 
transcription, integration or protease activity. 
Many natural products have been used as lead compounds because of their specific activity 
and low toxicity, and some have displayed mechanisms of action complementary to those of 
existing anti-virals (Jung et al., 2002; Singh et al., 2005). 
 
In addition, the vast chemodiversity of plant-derived compounds and secondary metabolites 
have vast potential as lead compounds in the drug discovery process (Verpoorte, 1998). These 
secondary metabolites are bioactive compounds that are produced by plants and may, for 
example, act as protective barriers against disease or pests, anti-feedants or even stimulate 
growth and repair (Verpoorte, 1998). 
 
There are currently no plant-derived antiviral drugs in clinical use for the treatment of HIV, 
2828  
although three natural products have shown promising activity in preclinical trials. According 
to Singh et al. (2005), phase II clinical trials are being conducted by Sarawak MediChem 
pharmaceuticals to determine the long term anti-HIV activity of Calanolide A (a coumarin). 
Two other molecules, licensed to Panacos Pharmaceuticals have completed preclinical testing, 












Figure 3: The Drug Development Process 
1.13.3 The Drug Discovery Process 
 
The initial steps in drug discovery are crucial in the development of an antiretroviral agent. 
An efficient screening process to determine the potential efficacy of an anti-HIV compound 
must allow for the expeditious determination of the most significant features of anti-HIV 
activity displayed by the agent (Buckheit, 1997). This process must also therefore, facilitate a 
cytotoxicity evaluation of the compound and allow the activity of the compound to be 
compared to known antivirals.  
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A variety of in vitro experiments can be performed to evaluate the anti-HIV efficacy and 
toxicity of a selected compound. Once an active compound is identified, many additional 
assays must be performed to determine the specific mechanisms of action which may include 
cellular and viral targets. 
 
 While biochemical assays may be employed to determine mechanisms of action, cell-based 
assays offer a holistic view of the affect of a compound on cellular activity. Both types of 
assays can be easily adapted to a high throughput screening approach with the use of robotics 
(Weislow et al., 1989). High-throughput screening is an invaluable tool in the drug discovery 
process. This method ensures that a large number of potential agents or drugs can be screened 
efficiently.  
 
The benefits and limitations of each assay, the type of screening facility and the information 
required about the potential drug must be considered when choosing an assay type. 
 
Biochemical assays do not require specialized bio-containment facilities and are very useful 
in providing a rapid method of determining the specific steps in the replication cycle. Many 
inhibitors of viral attachment, reverse transcription, integration and protease activity have 
been identified using these mechanism-based biochemical assays (Buckheit, 1993; Clancey et 
al., 1994, Hazuda et al., 1994; Hylans et al., 1990).  
However, these assays do not allow for the assessment of a potential compound’s ability to 
exert its mechanism of action in complete cells. 
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Cell-based assays do require specialized biosafety facilities and staff who have been trained in 
the implementation of specific safety practices. These assays may therefore not be an option 
for many institutions. The advantage of cell-based testing, however, is that the efficacy of a 
compound may be evaluated using intact human host cells. Furthermore, these assays can be 
used even before the mechanism of action of the potential compound has been determined. 
 
There are many cell-based assays which could be used for the evaluation of compounds for 
anti-HIV activity, including cytopathicity, syncytial and plaque assays. These assays have 
been used successfully to evaluate compounds using all known mechanisms of action 
(Sausville and Shoemaker, 2000).  
Another advantage of cell-based assays is that both cytotoxicity and antiviral activity may be 
screened for in parallel using the same target cell system. 
A further benefit of cell-based assays is that the “therapeutic index” of the compound can be 
defined (Buckheit, 1997; Weislow et al., 1989). This allows the comparison of the candidate 
compound within a class of known antivirals. 
 
Irrespective of the initial biochemical assays used in the anti-HIV drug discovery process, 
cell-based assays must eventually be performed, since the main goal of the preclinical 
screening process is to ascertain the toxicity and antiviral efficacy of the candidate compound 
in a human cell line representative of HIV infected cells in vivo. 
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For the high-throughput screening process to be successful, the assays must be appropriately 
performed, in a rapid and cost-effective manner in order to expedite the preclinical testing of a 
candidate compound. 
 
In this study a colorimetric cytotoxicity assay was optimised specifically for the testing of 
plant extracts. The documented methods employed in the testing of conventional compounds 
cannot be directly applied to plant derived products. For this reason, several modifications to 
conventional testing were designed and assessed in this study. An antiviral assay using a 
continuous HIV-infected cell line was developed to determine the anti-HIV efficacy of these 
extracts. Quantification of antiviral activity using established automated p24 antigen and viral 
load systems were compared. A new method of cell counting was designed as a safer and 
more efficient alterative to the well-known Trypan Blue Exclusion technique. The 
enhancements to the cell-based cytotoxicity and antiviral assays described in this study 
facilitate the adaptation of these techniques to the high-throughput screening of natural 
products. These enhancements have not previously been described in the literature and 
provide a platform for further research in this field. 
 
The future holds a greater understanding of this complex virus and new strategies for 
retaliation. Undoubtedly, extensive ongoing research efforts will result in an increase in the 






To develop, optimise and compare various virological assays for use in the antiviral 




• To maintain and propagate H9/HTLV IIIB transfected lymphoblastoid cells 
• To infect MT4 cells with HTLV IIIB and quantify the viral titre using the TCID50 
method  
• To develop a safer method of performing cells counts on HIV-infected cells 
• To compare the use of chronically infected H9/HTLV IIIB transfected lymphoblastoid 
cells  with MT4 cells infected de novo with  HTLV IIIB,  in the XTT assay 
• To optimise the XTT-based cytotoxicity assay for the rapid screening of plant-derived 
extracts 









Chapter 2: Cell and Virus Propagation and Quantification 
  
The objectives of this chapter were to maintain and propagate the three lymphocyte cell lines 
(uninfected H9, HTLV IIIB transfected H9 and MT4), describe the XTT method of cell 
quantification and the TCID50 method of viral quantification. 
 
2.1 Cell lines 
 
In adherent cell lines, cells adhere to the surface of a flask where they multiply and proliferate 
in a monolayer. The effect of viruses on a specific cell line can be detected without the need 
for an animal model. Cell lines can also be grown as suspension cultures in a flask, in which 
growth of the cells is maintained by RPMI-1640 rather than EMEM. 
A continuous cell line is one that has been transformed to give the cells an infinite life span. 
Primary cell lines, on the other hand, are more sensitive and cannot be cultured over long 
periods since they lose their natural morphology and integrity. 
 
Cells are generally maintained in media that has been supplemented with fetal calf or fetal 
bovine serum. Antibiotics such as, Penicillin, Streptomycin and Fungizone(Aphotericin-B)  
are added to the media to prevent the growth of bacteria and fungi in cell cultures. 
Cells require an environment conducive to growth and this is provided in the laboratory by 
sterile incubators, maintained at 37°C with 5% CO2. This provides a ‘natural’ buffering 
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system where the gaseous CO2 balances with the HCO3 content in the culture media to 
maintain an optimal pH environment for cell growth. Most media, including RPMI, change 
colour to either yellow (acidic) or purple (alkaline) indicating the need for replenishment. The 
pH indicator phenol red is contained in the media for this purpose. 
 
Cell lines can also be frozen indefinitely for use in the future, and this provides an advantage 
for laboratories in that a constant supply of stock cells can be made available. 
2.2 Constituents of Media 
 
Essentially, tissue culture is the propagation of animal, human or plant cells in vitro (George 
et al., 1996). The tissue is maintained in a specific media eg. Eagles Minimum Essential 
Media (EMEM) that has been fortified with serum. The basic constituents of media include 
inorganic salts, carbohydrates, amino acids, vitamins, fatty acids, lipids, proteins and peptides 
(George et al., 1996). Inorganic salts maintain cellular osmotic balance and the regulation of 
cell membrane potential by providing sodium, potassium and calcium ions. Carbohydrates 
provide the main energy source in the form of glucose, galactose, maltose or fructose. The 
main source of vitamins in media is derived from the addition of serum. However, some 
media types are commercially available enriched with vitamins. Vitamins are precursors for 
crucial co-factors as well as stimulators of growth and proliferation (B Vitamin family).  
Fatty acids and lipids such as cholesterol and steroids are usually found in serum and need to 
be supplemented in serum-free media. Trace elements, such as zinc, selenium and copper are 
present in media. Selenium is required for the removal of oxygen free radicals. 
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When used for tissue culture, media is generally supplemented with fetal calf (FCS) or fetal 
bovine serum (FBS). In some instances, horse serum may be used. Serum is an important 
component of media since it contains albumin, growth factors and inhibitors and has the 
ability to both increase the buffering capacity of cultures and protect cells from mechanical 
damage. Proteins present in serum such as fibronectin and fetuin aid in cell attachment while 
α-2macroglobulin inhibits trypsin. Transferrin binds to iron making it less toxic and more 
available to the cell. 
Polypeptides such as Platelet Derived Growth Factor stimulate mitogenic activity. Major 
Growth Factor, Fibroblast Growth Factor, Epidermal Growth Factor and Endothelial Growth 
Factor are also present. 
The hormone insulin promotes glucose and amino acid uptake, which enhances the mitogenic 
effect. Hydrocortisone present in serum is needed to stimulate cell attachment and 
proliferation. Metabolites and nutrients in serum include glucose, amino acids and ketoacids. 
 
Inhibitors, such as complement are also present in FCS and require removal by heat 
inactivation to prevent cytotoxicity. 
 
2.3 Propagation of cell lines 
 
For the purposes of the study, three cell lines were used: 
• Uninfected H9 
• HTLV IIIB transfected H9 




All cell lines were received from the National Institute of Health AIDS Research and 
Reference Reagent Program (Bethesda, USA). 
Description: 
The Human T lymphoblastoid, Hut 9 or H9 cell line is a clonal derivative of the T-cell line 
HUT 78 derived from the blood of a patient with Sezary syndrome. This clone was selected 
due to its suitability for the isolation and continuous high level production of HIV variants in 
patients with AIDS and pre-AIDS. Examination with DNA probes indicate identical HLA 
typing and DNA fingerprints to HuT-78 (Mann et al., 1989). Both uninfected H9 cells and 
HTLV IIIB transfected H9 cells were used for the purposes of this study. 





Each cell suspension was poured into 50ml centrifuge tubes (Cellstar, Greiner BioOne, USA) 
containing 10mls of fresh, warm, complete RPMI-1640 and centrifuged for 10 minutes at 
1500 rpm with no brake. The supernatant was poured off and the pellet reconstituted in fresh, 
complete RPMI-1640. Cells were grown in T25 tissue culture flasks (Corning Incorporated, 
USA) over a 5 day period. 
 
Quantification and Storage: 
Cell counts, using the Trypan Blue Exclusion Method (Appendix D), were performed on the 
uninfected H9 and uninfected MT4 cells in preparation for storing the cultures in liquid 
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nitrogen. This method of cell counting was not performed on the  HTLV IIIB transfected H9 
cells due to safety concerns since continuous cell lines may produce extremely high viral 
titres. Supernatant samples were therefore taken for viral load testing (NASBA NucliSens 
EasyQ (Biomerieux, Netherlands)) to determine viral titres prior to attempting conventional 
cell counts. The stored cell cultures were used for the XTT assay and subsequent antiviral 
assays. 
 
2.4 Virus - HTLV IIIMN 
 
 
The HTLVIIIMN cell-free virus was received from National Institutes of Health AIDS 
Research and Reference Reagent Program (Bethesda, USA). The virus was isolated from 
tissue culture supernatant of infected H9 cells and is free of bacteria, mycoplasma and fungi. 
It infects a wide variety of lymphocytes including CEM, H9 and MT4. It utilizes CXCR4 as a 
co-receptor and exhibits cytopathic effects. 
 
2.5 Inoculation of MT4 cell line with HTLV IIIMN 
 
A sample of the MT4 cell culture was centrifuged at 1500rpm for 5 minutes. The supernatant 
was removed and replaced with 1 ml HTLVIIIMN supernatant. The cells were re-suspended in 
the virus supernatant and incubated in a 37C, CO2 incubator for 1 hour.  10 ml PBS was 
added to the cells and centrifuged for 5 minutes at 1500rpm. The supernatant was discarded 
and the cells washed with PBS. The suspension was centrifuged at 1500rpm for 5 minutes and 
the wash step repeated. The supernatant was discarded and complete RPMI was added to the 
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cells. The culture was centrifuged at 1500rpm for 5minutes. 1ml of supernatant was retrieved 
for a qualitative baseline p24 test (see Appendix F). The cells were re-suspended in the media 
and planted in a 75cm3 flask. After incubating the flask for 3 days at 37C in a CO2 incubator, 
the cells were then centrifuged at 1500rpm for 5 minutes. 1000ul of virus supernatant was 
pipetted into labeled cryovials and stored at -800C or in liquid nitrogen for subsequent 
quantification by the TCID method and use in the XTT assay. 
 
2.6 Viral Quantification using the TCID50 method 
 
The TCID50 method is a well established and accurate technique used to quantify virus 
(DAIDS manual). It is based on statistical analysis of infectivity using end point dilution.  
2.6.1 Materials and Methods: 
 
150ul of complete colourless RPMI-1640 was added to rows B-H, columns 2-11 of a 96 well 
Microtitre plate. 50ul of HTLVIIIMN virus culture supernatant was pipetted into each well in 
rows B-G, column 2. Using a multichannel pipette a serial dilution (1in 4) of virus from 
column 2 to column 10 was performed. Column 11 was used as the cell control. A cell count 
was performed on exponentially growing MT-4 cells. The cells were then centrifuged at 1000 





50ul of cells were pipetted into each well. The plate was incubated for 5 days in a 37
0
C, CO2 
incubator. The plate was then read for cytopathic effect from day 1 to day 5 using phased-
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Figure 4: Results of TCID50 assay depicted as per the test 96 well plate 
 
Log TCID50 = L-d(s-0.5) 
 
L = log of lowest dilution 
D = difference between dilution steps 
S = sum of proportion of positive wells 
Note: For the dilutions in this protocol 
     L = 1 
           D = -1 
  S = 3 
1-(-1)(3-0.5) =3.5 








2.7 Cell quantification using the XTT method   
 
Trypan Blue Exclusion is the conventional method of counting cells but there are safety 
concerns particularly when this technique is used to count continuous, HIV-infected cells 
producing extremely high viral titres, such as the HTLV IIIB transfected H9 cells.  Since the 
XTT tetrazolium salt can be used to determine levels of cell proliferation (Berridge et al., 
1993), we investigated the relationship between formazan production in the XTT assay, 
measured by optical density, and cell number, determined by the Trypan Blue Exclusion 
Method. 
 
2.7.1 Materials and Methods 
 
Serial dilutions of a stock culture of HTLVIIIB transfected H9 cells were prepared. 
The cell suspensions were prepared according the protocol used for XTT assay preparation 
(Appendix E).150µl of cell suspension was pipetted into designated wells in a 96 well plate 
(CostarCorning Incorporated, USA). 20µl of XTT/PMS solution (Appendix C) were added 
to each well. The plate was incubated at 37°C with 5% CO2 for 2 hours. Absorbances were 
read using the Tecan Sunrise (Tecan Trading, Switzerland) Microplate reader and analysed 
using Magellan software. 
Several such experiments were performed on different stocks, using both infected and 
uninfected cultures. Cell counts were performed only on uninfected stock cultures using the 
Trypan Blue Exclusion Method (Appendix D). 
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The relationship between optical density (measured by the XTT assay) and cell counts in 
uninfected cultures (measured by Trypan Blue Exclusion) was determined by linear 
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Figure 5: Linear relationship between cell number and optical density reading using a 








Table 5: Linear regression output from STATA 
Cellcount Coef. Std. Err. T P>t [95% Conf. Interval] 
       
OD 620230.3 38165.26 16.25 0.000 514266.5 726194 
_cons -98955.1 8268.954 -11.97 0.000 -121913.4 -75996.8 
 
The result of one such experiment is shown in the above figure. The STATA output is 
shown in Table 5. 
 
A linear relationship was found between formazan production and cell number and can be 
expressed in the equation: 
Cell count = -98955.1 + (620230 x optical density). 
A similar linear relationship was found in other experiments on uninfected cells (data not 
shown).  
A linear relationship was found between serial dilutions and optical density in experiments 
with infected cells (data not shown) 
 
2.7.3 Implications of Results 
 
This method was applied to determine cell counts in infected and uninfected cultures for use 
in cell based assays.  
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Formazan production is a measure of cell proliferation and is proportional to cell number. 
Several factors such as viral infection and exposure to toxic substances may confound this 
relationship by affecting mitochondrial enzyme activity and hence formazan production. 
The linear equation may be different depending on the cell line used and in different stocks of 
cells. 
Nevertheless, this method is still useful. A linear equation can be derived for a stock of 
uninfected cells of a particular cell line and applied to infected stocks of the same cell line at 
the initial stages of infection. 
The results obtained are approximate. Further experiments are required to refine, validate and 














Chapter 3: The XTT assay - Optimisation of the assay for use 
when testing plant extracts 
 
This chapter documents the optimisation of the XTT-based cytotoxicity assay for the rapid 
screening of plant-derived extracts 
3.1 Principle of the XTT assay 
 
The use of colorimetric assays in cyotoxicity testing, particularly in the screening of antiviral 
compounds, is an indispensible tool. Previously, methods such as the counting of viable cells 
stained with a vital dye or the measurement of radioisotope incorporation as a measure of 
DNA synthesis were used to determine the in vitro cytotoxic effects of unknown compounds. 
There are issues of safety, test sensitivity as well as accuracy with these methods.  
Tetrazolium salts are commonly used in cytotoxicity, cell viability and cell proliferation 
assays (Berridge et al; 1993). Once reduced, these salts are converted into non-fluorescent 
formazans which precipitate out of the solution, and can either be used in the localisation of 
the site of reduction or solubilised and quantified (Sladowski. et al;1993, Specter et al; 2000). 
 
Assays making use of tetrazolium salts have become the gold standard of such techniques. 
The description of the MTT assay in the early 80’s, was followed by the synthesis of 2,3-bis 
(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide or 
XTT (Paull et al., 1988). The XTT assay offers a more simplified approach with its water 
soluble formazan product that is easily measured in cellular supernatants (Altman, 1976; 
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Kuhn et al., 2003; Roehm et al., 1991). This assay uses a colorimetric technique that offers 
rapid quantitative analysis of the inhibition of HIV-induced cell killing by anti-HIV test 
substances by determining cell viability. 
 
The assay is based on the conversion of the yellow XTT tetrazolium salt into a soluble orange 
formazan by metabolically active cells. This process occurs as a result of mitochondrial 
dehydrogenases cleaving the tetrazolium ring resulting in formazan production (Kuhn et al., 
2003). Other enzymes involved in the process include mitochondrial succinoxidase as well as 
cytochrome p450 systems and flavoprotein oxidases (Altman, 1976).  
However, since the bioreduction of XTT is an inefficient process, an electron coupling agent 
called phenazine methosulfate (PMS) is added to the reaction (Berridge et al., 1993). The 
soluble formazan can be quantified using an ELISA reader. 
The use of techniques such as the MTT or XTT assays when screening compounds has 
therefore proven to be greatly advantageous in that the salts are safe, since no radioactive 
isotopes are used; accurate, because tetrazolium salt conversion correlates strongly with 
metabolic activity and sensitive, since fairly low cell numbers can be used. 
Since the assays may be carried out in microtitre plates and the quantification requires only 
multi-well ELISA readers, this assay also has the advantage of being both rapid and cost 
effective and is thus a useful tool in cytotoxic analyses of compounds when investigating 
antiviral susceptibility. Tetrazolium salts are also valuable tools in the determination of cell 
proliferation (Berridge et al., 1993). This study explored the use of this property in the 
development of an alternative cell counting assay. 
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3.2 Potential problems with the XTT Assay when testing plant extracts: 
 
Plant extracts were obtained from the CSIR Bio-Prospecting Unit (Pretoria). This unit has a 
library of natural products, some of which have been purported to have potential antiviral 
activity. Both ethanolic and aqueous extracts of these natural products material were to be 
screened using the XTT assay, to determine cytotoxic effects as well as dose ranges. 
Extracts found to have optimal selectivity indices were to be tested for antiviral effects in 
infected cell cultures. 
 
 
Figure 6: Factors influencing the optimisation of the XTT assay for the cytotoxic evaluation 
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The following factors were considered when testing plant extracts for cytotoxic activity 
(Figure 6). These factors have not been clearly addressed in the current literature.  
 
1. RPMI containing phenol red indicator 
 
The XTT/PMS solution is pale yellow in colour (Tox2 Kit package insert, Sigma). XTT is 
reduced by the activity of cellular enzymes, producing a formazan which is orange in 
colour. However, RPMI, containing phenol red, is metabolised by cells during assay 
incubation resulting in the change in the phenol red indicator to a yellow/orange colour. 
This yellow/orange colour of RPMI is also read at the wavelength required for formazan 
optical density measurement and compromises the results of the assay.  
 
2. Toxic effect of DMSO on cells 
 
Phenolic plant extracts may require reconstitution in either 100% or 50% DMSO to enable 
their complete solubility prior to testing (CSIR-BioProspecting Unit, personal 
communication Dr Vinesh Maharaj). DMSO is known to be toxic to cells (DMSO 
package insert). This would be a potentially confounding factor in interpreting the results 
of the cytotoxicity assay.  
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3. XTT conversion to soluble formazan in cell-free conditions 
       
Plant extracts are likely to contain various plant enzymes which have the potential to 
reduce the tetrazolium salt to formazan. Also, since XTT requires the intermediate 
electron acceptor PMS, this salt can be reduced by NADH and NADPH in the absence of 
cells and enzymes (Berridge et al., 1993). It was also shown by Berridge et al. (1993) that 
superoxides play a vital role in XTT reduction in the absence of cells. The production of 
formazan by the activity of plant enzymes can mask decreased formazan production due 
to cytotoxicity. 
3.3 Optimisation Experiments 
1. Experiment with RPMI with and without phenol red indicator 
 
A. The standard XTT assay method (4.2.3) was performed using RPMI with and without the 
phenol red indicator (RPMI-1640, and RPMI-1640 modified media respectively). No cells 
were used in this experiment. 
150 µl of complete RPMI, with and without phenol red, was pipetted into each of 10 wells 
wells in a 96 well microtitre plate (CostarCorning Incorporated, USA ). 
The plates were read at 450nm/620nm on TECAN Sunrise ELISA plate reader and 
Magellan software (Tecan Trading, Switzerland). 
20µl XTT/PMS was added to each well. 
The plate was incubated for 4 hours at 37°C with 5% CO2. 
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The plates were then read at 450nm/620nm on TECAN Sunrise ELISA plate reader and 
Magellan software (Tecan Trading, Switzerland). 
 
B. The standard XTT assay method was performed using RPMI with and without the phenol 
red indicator (RPMI-1640, and RPMI-1640 modified media respectively). 
150 µl of uninfected H9 cell suspension, made up in complete RPMI with and without phenol 
red, was pipetted into each of 10 wells wells in a 96 well microtitre plate (CostarCorning 
Incorporated, USA). 
The plates were read at 450nm/620nm on TECAN Sunrise ELISA plate reader and 
Magellan software (Tecan Trading, Switzerland). 
20µl XTT/PMS was added to each well. 
The plate was incubated for 4 hours at 37°C with 5% CO2. 
The plates were then read at 450nm/620nm on TECAN Sunrise ELISA plate reader and 
Magellan software (Tecan Trading, Switzerland). 
 
The difference in OD readings before and after incubation with XTT (∆) was calculated and is 








Table 6: The difference in OD readings before and after incubation with XTT (∆) and 
corresponding p values 













∆ 0.0623 0.0827 0.0765 0.1007 
p value 0.0145 0.0182 
 
There was a statistically significant difference in the mean difference pre and post XTT-
incubation i.e.∆, between RPMI with and without phenol red indicator (p = 0.0182) (t-test 
STATA 10, College Station, Texas, USA). The mean OD values are shown in table 4. 
 
It is not sufficient to merely subtract the baseline ODs ie before addition of XTT, from the 
post-incubation OD readings. The results of this experiment demonstrates that the subtraction 
of pre from post ODs does not cancel the effect of the phenol red indicator. The alteration in 
the colour of the phenol red indicator is possibly due to a pH change during the course of 
incubation. As a result RPMI containing indicators such as phenol red cannot be used in 
colorimetric cytotoxicity screens such as the XTT assay. The use of colourless RPMI is 
therefore essential.  
 
2. Experiment to determine effect of DMSO on cells 
 
Cells were exposed to varying concentrations of DMSO constituted in complete colourlesss 
RPMI.  
The standard XTT assay was performed as per 4.2.3. 
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150µl of these cell suspensions were pipetted in replicates into wells of a 96 well microtitre 
plate. 20µl of XTT/PMS was added to each well. The plate was incubated for 4 hours at 37°C 
with 5% CO2. The plate was then read at 450nm/620nm on TECAN Sunrise ELISA plate 
reader.  
The average OD readings are tabulated below. 
 
Table 7: The average optical density readings pre and post incubation with XTT in cell 








0.19 0.240 0.239 0.209 
After 4 hr 
incubation 
with  XTT 
1.587 1.526 1.505 0.285 
 
Student’s t test was performed to determine the significance of the difference between OD 
readings in wells with concentrations of DMSO ≤ 0.625 % DMSO and ≥ 6.25% DMSO. 
 
A statistically significant difference was found between the 2 groups, with mean OD 1.546 
and 0.285 with ≤ 0.625 % DMSO and ≥ 6.25% DMSO respectively (p < 0.0001). 
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3. Experiment to investigate XTT conversion to soluble formazan in cell-
free conditions. 
We conducted experiments to study the effect of cell-free plant extracts on formazan 
production.  
Dilutions of plant extracts (0µg/ml; 0.25µg/ml; 2.5µg/ml and 25µg/ml) were prepared in 
colourless RPMI-1640 modified media. 
The standard XTT assay was performed as per 4.2.3. 
150µl of each concentration was pipetted into wells of 96 well microtitre plates (10 wells per 
concentration). 
The plates were read at 450nm/620nm on the TECAN Sunrise Microplate Reader. 
20 µl of XTT/PMS was added to each well and the plates were incubated for 4 hours at 37°C 
with 5%CO2. 
 The plates were read at 450nm/620nm on the TECAN Sunrise Microplate Reader. 
The difference, ∆, in OD reading before and after incubation with XTT was calculated. The 
mean baseline OD readings are shown in Table 7. 
 




0 µg/ml 0.25µg/ml 2.5µg/ml 25µg/ml 
 Mean baseline 
OD 
0.0489 0.0339 0.0341 0.0475 
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We found no statistically significant difference between ∆ of the control ie. 0µg/ml and ∆ of 
each of the other concentrations. This suggests that there is no apparent effect of plant 
enzymes on formazan production. 
However, there were significant differences between the baseline OD of the control and each 
of the concentrations of the extract (p<0.05). This finding suggests that the colour of the 
extract is a significant factor in OD calculations in the XTT assay. To account for this, pre and 
post XTT incubation OD readings were performed in all subsequent experiments.  Pre-
incubation OD readings were subtracted from post incubation OD readings. This modification 














Chapter 4: The XTT assay - Chronically infected versus 
experimentally infected cells  
 
This chapter describes the comparison between the use of two cell lines (chronically infected 
HTLV IIIB transfected H9 cells and MT4 cells that were experimentally infected with HTLV 
IIIMN) in the XTT assay.  
 
4.1 Overview and rationale of the experiments 
• Both chronically infected and de novo infected cells have been used in published XTT 
protocols (Weislow et al, 1989). Since these methods may yield varying results, we 
compared their use in the cytotoxicity screening of plant extracts.  
• Chronically infected HTLV IIIB transfected H9 cells were propagated and exposed to 
plant extracts and AZT 
• Uninfected MT4 cells were infected de novo with the HTLVIIIMN strain and exposed 
to the plant extracts and AZT 
• The XTT assay was performed on both the XTT and MT4 cell lines. 
4.2 Materials and Methods 
4.2.1 Incubation of uninfected H9 and chronically infected HTLV IIIB H9 cells 
with plant extracts and test reagents 
The outer wells of a flat bottomed, 96-well plastic microtiter plate (CoStar, Corning 
Incorporated, USA) were filled with 200 µl of phosphate buffered saline (PBS). 
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500µl of HTLV IIIB transfected H9 cell suspension (as prepared in 2.1.2), of the final cell 
concentration to be used was added to each labelled 1ml eppendorf tube. The tubes were spun 
at 1500 rpm for 10 minutes. The supernatant was discarded and 500µl of the appropriate 
concentration of the plant extract compound/AZT/test reagent/RPMI (Appendix C), made up 
in complete colourless RPMI, was added. The tubes were vortexed gently to reconstitute the 
cells. 150µl of this cell suspension was pipetted into each well, in triplicate. 
This process was repeated with 500ul of uninfected H9 (as prepared in 2.1.2) cell suspension. 
 
The infected and uninfected plates were incubated at 37
0
C in a CO2 incubator for 5 days. The 
cells remained in contact with the test compounds during the entire incubation period. Five 
days after infection the viability of the uninfected and HIV infected cells was determined 
spectrophotometrically by the XTT assay (see 3.3.1.3). 
  
 
4.2.2 Experimental infection of MT4 cells with HTLV IIIMN MT4 cells and 
incubation with plant extracts and test reagent 
Flat bottomed, 96-well plastic microtiter plates (CoStar, Corning Incorporated, USA) were 
filled with 100µl of complete medium containing dilutions of test compounds (Appendix C) 
using a multichannel pipette. These dilutions were performed in triplicate to allow 
simultaneous evalution of their effects on HIV-infected and uninfected cells. Untreated HIV-
infected and uninfected cells were included as controls for each compound. AZT, DMSO and 
RPMI were used as controls.  
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A flask of exponentially growing MT-4 cells was centrifuged for 5 minutes at 1000 rpm and 
the supernatants discarded. The cells were re-suspended in colourless RPMI-1640 at 6 x 105 
cells/ml. 50ul were pipetted into each well. 10ul of 100TCID50 was used for the experiments. 
 The outer wells of the plate were filled with 200 µl of phosphate buffered saline (PBS). 50 µl 
of HIV (HTLV IIIMN) supernatant at 100 TCID50 or RPMI was added to either infected or 
mock-infected wells. The plate was incubated at 37
0
C in a CO2 incubator for 5 days. The cells 
remained in contact with the test compounds during the entire incubation period. Five days 
after infection the viability of the mock- and HIV-infected cells was determined 
spectrophotometrically by the XTT assay. 
 
 
4.2.3 Standard XTT assay 
The In Vitro XTT based Toxicology Assay Kit (Sigma-Adrich, Missouri, USA) was used. 
The XTT assay was performed according to Scudiero et al. (1988), Weislow et al. (1989), and 
Cos et al., (2002) with modifications. 
 
The kit contained XTT +1% PMS in 5mg vials. 
The XTT/PMS reagent was made up according to manufacturer’s instructions (Appendix C). 
20µl of XTT/PMS reagent was added to each test and control well. The plates were then 
incubated for a further 4 hours at 37°C with 5% CO2 before being read at 450nm, with a 
reference wavelength of 620 nm using the Tecan Sunrise ELISA plate reader and Magellan 
software. (Tecan Trading, Switzerland) 
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The percentage protection was determined by the following equations using the recorded 
absorbances (Cos et al., 2002): 
Uninfected cells:  
Optical Density reading for uninfected untreated = A = 100% 
Optical Density readings at varying concentrations  = Y 
Formula for % of uninfected treated cells:  
% of uninfected treated cells = (Y/ A) x 100 
 
Infected: 
Optical Density reading for infected untreated = B  
Optical Density readings at varying concentrations = X 
Formula for % protection  
 
% Protection = [(X – B) / (A-B) ] x 100 
 
CC50 (50% cytotoxic concentration) is defined as the concentration of the test compound that 
reduces the absorbance of the uninfected control by 50%. 
 
EC50 (50% effective concentration) is defined as the concentration of the test compound that 





We derived an equation based on linear extrapolation to determine the EC50 from the values 
obtained in the experiment: 
EC50 = V – {[(W-50%) / (W-U)] x (V-T)} 
 
where,  
V = is the concentration of the test compound that corresponds to the closest percentage 
above 50% 
W= is the closest percentage above 50% 
U= is the closest percentage below 50% 
T= is the concentration of the test compound that corresponds to the closest percentage below 
50% 
 









4.2.4 Results of the XTT assay using chronically infected versus experimentally 
infected cell lines 






































Figure 7: H9 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of AZT. 
 


































Figure 8: MT4 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of AZT. 
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Figure 9: H9 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract LA5B. 
Cell viability in uninfected cells remained above 80% up to the 25µg/ml concentration. 
Percentage protection in chronically infected cells increased to ~70% at 0.25µg/ml of the 
extract (Figure 9). 



































Figure 10: MT4 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract LA5B. 
The sharp decline in % cell viability is due to the cytotoxic effect of the plant extract at 
7.9ug/ml. The extract does not demonstrate a protective effect i.e. the % protection does not 
reach 50% (Figure 10). 
 






































Figure 11: H9 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract MM166A. 
Cell viability in uninfected cells remained above 60% in all concentrations. Percentage 
protection increased to ~70% at 0.25µg/ml of the extract in infected cultures (Figure 11). 
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Figure 12: MT4 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract MM166A. 
The extract does not demonstrate a protective or cytotoxic effect since neither the % cell 
viability nor % protection reaches 50% (Figure 12). 
 






































Figure 13: H9 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract MM166B. 
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The extract appears to be toxic at the lowest concentration (0.25µg/ml) in uninfected cultures. 
Protection in infected cultures is apparent at the lowest concentration (0.25µg/ml) of the 
extract (Figure 13). 
 


































Figure 14: MT4 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract MM166B. 
The sharp decline in % cell viability is due to the cytotoxic effect of the plant extract at 
25ug/ml. The extract does not demonstrate a protective effect i.e. the % protection does not 











































Figure 15: H9 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract MM166C. 
The extract appears to be toxic at the lowest concentration (0.25µg/ml) in uninfected cultures. 
~ 100% protection in infected cultures is apparent at the lowest concentration (0.25µg/ml) of 
the extract (Figure 15). 
 



































Figure 16: MT4 cell viability in uninfected cultures and cell protection in infected cultures 
treated with varying concentrations of extract MM166C. 
The sharp decline in % cell viability is due to the cytotoxic effect of the plant extract at 
25ug/ml. The extract does not demonstrate a protective effect i.e. the % protection does not 
reach 50% (Figure 16). 
 
The EC50, CC50 and Selectivity indices of the extracts are shown in Table 9.  
 
Table 9: EC50, CC50 and Selectivity Indicies (SI) of AZT and the four plant extracts tested 
Extract 
Chronically infected H9 cell line Experimentally infected MT4 cells 
EC50  CC50  SI EC50  CC50  SI 
AZT 0.08 >250 3125 0.08 53.4 650 
LA 5B 0.181 >250 >1381.2 >250 179.2 <1 
MM 166A 0.169 >250 >1479.3 >250 0.0037 <1 
MM 166B 0.1506 ~0.25 1.66 >250 179.8 <1 
MM 166C 0.1405 ~0.25 1.78 >250 153.3 <1 
 
AZT demonstrates an SI of 3125 and 650. Both are in keeping with published values of the 
selectivity index of AZT which range from 400 to 24000 (Balzarini et al.,1989 ; Franchetti et 
al., 1998; Turk et al., 2002 and Weislow et al., 1989). Extracts LA5B and MM166A showed 
favorable selectivity indices with the chronically infected H9 cells but not with the 
experimentally infected MT4 cells. These extracts were therefore selected for further testing 
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using the antiviral assay. Extract MM166B and MM166C demonstrated little or no antiviral 























Chapter 5: A Cell-based Antiviral Assay using p24 and Viral Load 
Quantification Methods 
The objective of this chapter is to compare the p24 assay and viral load assay as methods for 
assessing antiviral activity 
5.1 Antiviral testing 
 
Antiviral testing is a laborious and time-consuming process that does not guarantee the 
discovery of a lead compound. This is related to the fact that most antiviral drugs have been 
discovered in specialised commercial chemistry laboratories and not in prominent 
pharmaceutical industries (Oxford et al., 2000). 
 
However, in the search for novel agents with anti-HIV properties, new and improved in vitro 
screening methods have become a fundamental tool in improving the antiviral screening 
process.  
 
HIV susceptibility testing uses PBMC co-cultivation in order to assess the susceptibility of 
clinical HIV isolates to known or potential antiviral agents. This is done by comparing the 
concentration of the drug needed to inhibit the clinical isolate with that of a wild type 
reference strain (Haubrich, 2004). 
 
Cell culture, particularly novel methods of growing suspension cultures of human T cells, 
plays an important role in screening of agents with antiretroviral properties. T-cells that have 
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been transfected to permit a continuous life span are therefore an invaluable tool for use in 
antiviral testing (Oxford et al., 2000). In addition, 96-well plates that have been manufactured 
with a special coating to permit cell culture have the added advantage of suitable optical 
characteristics. The latter allows for the use of colorimetric antiviral-assays which require 
plates to be read by an ELISA reader, an advantage that has enabled high-throughput antiviral 
drug-screening (Oxford et al., 2000).  
 
The main purpose of the testing method described in this chapter was to develop a cell-based 
assay that could be used efficiently in the high throughput screening of agents with 
antiretroviral potential.  
Al-Jabri et al. (1996) and Oxford et al. (2000) describe a method for in vitro antiviral assays 
where a selected cell line, known to be susceptible to infection by the particular virus, is 
incubated with the test compound. Thereafter, cell-free virus stock is added to the cells, and 
the culture is grown over a fixed time-period. An appropriate drug control, which is known to 
reduce the activity of the virus, must be used. If the test compound has any antiviral effects, 
the ability of the virus to infect cells or replicate will be reduced. Virus replication is usually 









5.2 Viral quantification methods 
  
For the purposes of this study, viral quantification was performed using a quantitative p24 
antigen electrochemiluminescent assay (ECLIA) as well as a viral load assay.  
 
The Roche Cobas p24 kit and Roche Modular analyser (Roche Cobas, Elecsys and Modular 
analytics, Germany) was used to determine the amount of p24 in each sample. This type of 
p24 assay requires the interaction of the sample with biotinylated monoclonal HIV p24-
specific antibodies as well as Ruthenium complex labelled monoclonal HIV p24 specific 
antibodies to form a sandwich complex in an initial incubation step. Streptavadin-coated 
microparticles are then added, following a second incubation which allows for the interaction 
between the strepavidin and biotin. The reaction mixture is then transferred to a measuring 
cell where the microparticles are magnetically captured onto an electrode. Unbound reagent 
and sample are removed by washing, after which a voltage is applied to induce a 
chemiluminecsent emission. This signal is measured by a photomultiplier and the results are 
determined automatically by comparing the electrochemiluminescent signal from the sample 
with the cutoff value obtained by previous calibration 
 
 
The NASBA NucliSens EasyQ (Biomerieux, Netherlands) was used to measure viral RNA 
levels in the samples. 
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HIV-1 Viral loads have become an indispensable tool in the initiation and monitoring of 
antiretroviral therapy. Viral loads may also predict efficacy of treatment and be of prognostic 
significance (Wuesten et al., 2002). 
The NucliSens EasyQ system, employed for the purposes of this study, combines a technique 
known as NASBA RNA amplification (Van Gemen et al., 1993; Lin et al., 1998; Yen-
Lieberman, 1998; Biomerieux, 2002) with a real-time detection method that used molecular 
beacons. 
The initial step involves ‘Boom’ extraction, which is a method incorporating solid phase 
based nucleic acid release and isolation. The advantage of this method is that nucleic acids 
can be isolated from various sources including whole blood, serum, cerebrospinal fluid, 
semen, urine, vaginal lavage, saliva and most importantly for the purposes of this study, cell 
culture fluid (Bartlett, 1999). Also, the ‘Boom’ method is compatible with all anticoagulants 
and has a broad range of input volumes. 
There are essentially 4 stages in the NucliSens HIV-1 EasyQ assay: 
Nucleic acid release is accomplished by adding the sample to the Lysis buffer, containing 
guanidine thiocyanate and Triton X-100, which degrades debris and cells and inactivates 
RNases and DNases. 
 
Nucleic acid isolation: In addition to the nucleic acid from the sample, synthetic RNA that is 
used as an internal control and calibrator, is added to the Lysis buffer. These RNA constructs 
are required to produce a calibration curve required for the quantification process. The 
calibrator RNA differs from the sample RNA by only a small sequence. Under high salt 
conditions all the nucleic acid in the lysis buffer becomes bound to silica dioxide particles, 
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which act as the solid phase. The silica-bound nucleic acids are washed several times in wash 
buffer to remove all lipids and proteins and finally, purified nucleic acid is eluted. 
 
Amplification of nucleic acid is based on primer extension and repeated transcription of both 
sample RNA and calibrator RNA from intermediate DNA molecules produced by T7-RNA 
polymerase (Weusten et al., 2002). Three important enzymes, avian myeloblastosis virus 
reverse transcriptase, RNase H and, as mentioned earlier, T 7 RNA polymerase are required 
for the process, in addition to two primers, which are short single-stranded DNA fragments, 
one of which contains a T 7 RNA polymerase promoter which binds to HIV RNA. The 
amplification is isothermal and takes place at 41°C. During the reaction, reverse transcriptase 
generates a single DNA copy of the viral RNA sample (sense strands) once the first primer 
has bound. This results in the production of an RNA:DNA hybrid. RNase H hydrolyses the 
RNA strand and the second primer binds to the remaining DNA strand. The DNA polymerase 
activity of reverse transcriptase then extends the second primer to produce a double stranded 
copy of the original sense RNA with an intact T 7 RNA polymerase promoter. T 7 RNA 
polymerase recognises the promoter and generates transcription of antisense RNA. From the 
antisense strands, new DNA copies are generated in a process similar to that using the sense 
RNA strands, except that the second primer binds first, and the final product is double 
stranded DNA with the T7 promoter so that new RNA may be produced once again.                       
Nucleic acid detection: Since the anti-sense RNA produced cannot be detected on its own, 
molecular beacons are added to the sample which bind to the RNA. The total fluorescence 
signal generated by this complex is used to determine the concentration of the RNA 
(Biomerieux Training Manual). 
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5.3 Materials and Methods: 
5.3.1 Incubation of chronically infected HTLV IIIB H9 cells with plant extracts 
and test reagents 
Concentrations of AZT and plant extracts to be tested were made up in complete colourless 
RPMI (Appendix C). 
Cell counts were performed on infected H9 cells according to the XTT method described in 
Chapter 3. 
100µl of the HIV-infected H9 cell suspension and 400µl uninfected H9 cell suspension were 
pipetted into 1ml Eppendorf tubes. The tubes were spun at 1500rpm for 5 minutes. The 
supernatant was discarded and the pellets were washed twice in 10ml warm PBS by 
resuspending the pellets in the volume of PBS in 50ml tubes (Cellstar Greiner BioOne, 
USA), centrifuging at 1500rpm for 5 minutes, discarding the supernatant and replacing with 
fresh warm PBS. The process was repeated and the final pellet was resuspended in 3ml of 
concentration of AZT or test extract. A drug/extract free control was included in each cell 
system. 
The cell suspensions were pipetted into wells in 6-well plates (Sterilin, Great Britain) and the 
plates were incubated at 37°C with 5% CO2 for 6 days. A supernatant sample was taken from 
the drug/extract free control well on Day 1 after plating. Wells were sampled at Days 3 and 6. 
100ul of each supernatant sample was pipetted into tubes and tested using the Roche p24 
ECLIA (Appendix G). 500µl of each supernatant sample was taken for viral load testing. The 
viral load assay was performed on the supernatant samples according to package insert and 
accompanying protocol (Appendix H). 
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5.3.2 Experimental infection of MT4 cells with HTLV IIIMN MT4 cells and 
incubation with plant extracts and test reagent  
Concentrations of AZT and plant extracts to be tested were made up in complete colourless 
RPMI (Appendix C). 
Cell counts were performed on uninfected MT4 cells according to the Trypan Blue Exclusion 
Method (Appendix D). 
500µl of the uninfected MT4 cell suspension was pipetted into 1ml Eppendorf tubes. The 
tubes were spun at 1500rpm for 5 minutes. The supernatant was discarded and the pellets 
were resuspended in 3ml of concentration of AZT or test extract. A drug/extract free control 
was included in each cell system. The cells were incubated with the AZT or test extract for 30 
minutes at 37°C to allow for drug/cell equilibrium to be reached.  50 µl of HIV (HTLV IIIMN) 
supernatant at 100-300 TCID50 was added to each cell suspension containing the different 
dilutions of AZT or test extract. The cell suspensions were incubated for 3 hours at 37°C with 
5% CO2. The cells were washed twice in 20ml RPMI by resuspending the pellets in the 
volume of PBS in 50ml tubes (Cellstar Greiner BioOne, USA), centrifuging at 1500rpm for 
5 minutes, discarding the supernatant and replacing with fresh warm RPMI. The process was 
repeated and the final pellet was resuspended in 3ml of concentration of AZT or test extract. 
A drug/extract free control was included in each cell system. 
 
The cell suspensions were pipetted into wells in 6-well plates (Sterilin, Great Britain) and the 
plates were incubated at 37°C with 5% CO2 for 6 days. A supernatant sample was taken from 
the drug/extract free control well on Day 1 after plating. Wells were sampled at Days 3 and 6. 
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100ul of each supernatant sample was pipetted into tubes and tested using the Roche p24 
ECLIA (Appendix G). 500µl of each supernatant sample was taken for viral load testing. 
(Al-Jabri et al.,1996). 
 
The viral load assay was performed on the supernatant samples according to package insert 
and accompanying protocol (Appendix H). 
 
5.4 Results: 

















Figure 17: p24 concentrations at Day 6 of the antiviral assay performed on chronically HIV-
infected H9 cell cultures treated with varying concentrations of AZT 
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Figure 18: Viral load measurements at Day 6 of the antiviral assay  performed on chronically 
HIV-infected H9 cell cultures treated with concentrations of AZT 
 
The experiments were repeated several times and showed consistent results. 
The p24 results fail to demonstrate the efficacy of AZT even at the highest concentration of 
the drug. 
The viral load measurements show the reduction of viral replication at 10 µM of AZT. 
 
In order to establish the accuracy of the p24 assay, we performed p24 measurements of 10 
fold serial dilutions of virus stock. The concentration of p24 as measured by the ECLIA 















Figure 19: p24 concentrations of serial dilutions of viral stock as measured using the p24 
ECLIA 
 
The results are shown in Figure 19. This demonstrates the linear range of the assay and 
confirms its accuracy. 
We also found that extremely large amounts of cell and virus free p24 antigen were produced 
in the robust HIV infected continuous cell cultures used in the study. Several thousand-fold 
dilution of the supernatants were necessary to allow p24 antigen concentrations to fall within 
the linear range of the assay.   
It was also found that even after several washes of infected cell pellets and reconstitution in 
fresh RPMI, inconsistent baseline readings were still obtained and p24 concentrations were 
very high. Such high p24 concentrations, even in freshly seeded cultures of HTLV transfected 
H9 cells could be attributed to residual cell and virus free p24 antigen that remained on cell 
surfaces and the long half-life of p24 antigen. 
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Table 10: Viral load measurements on supernatant samples from chronically infected H9 
cultures (Baseline and Day 6). Values are expressed as copies per ml x 109. 
 Day 0 
copies per ml x 10
9 
Day 6 




Control for plant extracts 3.7 31 0.92 
LA5B 250µg/ml 3.7 12 0.51 
MM166A 250µg/ml 3.7 11 0.51 
Control for AZT 5.1 6.8 0.12 
AZT 0.1µM 5.1 6.2 0.08 
AZT 10µM 5.1 3.4 -0.18 
AZT 100µM 5.1 3.2 -0.2 
 
We exposed chronically HIV-infected H9 cultures to various concentrations of AZT and the 
test compounds LA5B and MM166A and measured the viral load at baseline and at day 6 post 
exposure. Table 10 shows the results for a range of concentrations of AZT, and the optimal 
concentration of the extracts as calculated by the XTT assay. The log difference between 
baseline and Day 6 viral loads is also shown. 
 
The log differences in the VL experiments clearly illustrate the efficacy of AZT in reducing 
viral replication at concentrations above 10µM. 
The log differences for extracts LA5B and MM166A is less than that of the control. 
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 The increase in viral load in the control exceeds the increase in viral load in experiments 
using the extracts. It is therefore possible that these extracts decrease viral replication in vitro 
at these concentrations. 
The experiments were repeated and the results yielded the same conclusion (results not 
shown) 
 
The p24 assay did not demonstrate the reduction of viral titres by AZT in repeated 
experiments. In contrast, the viral load did show a reduction of viral replication with 10µM 
AZT. 
 

















Figure 20: p24 concentrations at Day 6 of the antiviral assay performed on experimentally 




















Figure 21: Viral load measurements at Day 6 of the antiviral assay performed on 
experimentally HIV-infected MT4 cell cultures treated with concentrations of AZT 
 
The experiments were repeated several times and showed consistent results. 
The p24 results clearly demonstrate the efficacy of AZT. The viral load measurements show 


















Table 11: Viral load measurements on supernatant samples from experimentally infected MT4 
cultures (Baseline and Day 6). Values are expressed as copies per ml x 103 
 Day 0 
Copies per ml x 10
3 
Day 6 




Control for plant extracts 28 1500 1.7 
LA5B 250µg/ml 22 970 1.6 
MM166A 250µg/ml 17 2200 2.1 
Control for AZT 46 490 1.0 
AZT 0.1µM 23 730 1.5 
AZT 1µM 14 550 1.6 
AZT 10µM 10 73 0.9 
AZT 100µM 9.6 11 0.059 
 
Experimentally HIV-infected MT4 cells were exposed to various concentrations of AZT and 
the test compounds LA5B and MM166A. The viral loads were measured at baseline and day 
6 post exposure. Table 11 shows the results for a range of concentrations of AZT, and the 
optimal concentration of the extracts as calculated by the XTT assay. The log difference 






Chapter 6: Discussion 
 
The AIDS pandemic is considered to be one of the most devastating scourges of all time. 
UNAIDS has estimated that 40.3 million people globally, and 5.5 million people in South 
Africa were living with HIV in 2005. An estimated 2.8 million people worldwide died of the 
disease in 2005 alone, of which 2 million deaths occurred in Sub-Saharan Africa.  
A large arsenal of drugs is available that can be used to improve the quality of life of infected 
individuals. However, this form of treatment does not achieve viral clearance and requires 
lifelong therapy. Furthermore poor adherence and the development of resistance are 
implicated in the failure of antiretroviral therapy. Options are limited by overlapping toxicities 
and cross-resistance between classes of anti-retrovirals.  
 
As a result, a need exists for new drugs to help in the treatment of HIV infection. These drugs 
may either be a modification of existing drugs, or completely novel agents. Such novel drugs 
may either have similar mechanisms of action as current classes of drugs or have completely 
new targets. 
 
However, the process of new drug discovery is time-consuming and resource intensive. It 
generally takes years to see the development of a new antiviral drug to completion, from 
discovery to preclinical testing, all the way through to clinical trials. The initial screening 
process is probably the most critical step in the new drug discovery process because it is here 
that the cytotoxic and antiviral properties of a potential agent are first identified. 
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The purpose of this study was the development of an initial screening process that could be 
adapted to a high-throughput environment for the testing of agents with potential 
antiretroviral activity. 
 
All methods were compared using a chronically infected HTLV IIIB H9 cell line and MT4 
cells that were newly infected with HTLV IIIMN prior to use in the experiments. The 
established TCID50 technique was used in order to quantify the virus used to infect the MT4 
cells. The results were calculated using the Spearman-Karber method.  
 A safer method of performing cell counts on HIV infected cultures was explored since viral 
titres in HIV-transfected H9 continuous cell line were found to be extremely high rendering 
the usual methods of cell counting unsafe. This method, described in Chapter 2, adapted the 
use of XTT as an indicator of cell proliferation (Berridge et al., 1993). A regression equation 
was derived which illustrated the linear relationship that was found between formazan 
production and cell number. This technique was used as an alternative to the Trypan Blue 
Exclusion Method to determine cell numbers in both uninfected and HIV-infected cultures. 
 
 
The next objective of the study focused on the optimization of the XTT tetrazolium-salt based 
cytotoxicity assay for the testing of plant extracts. Several factors were considered that were 
unique to the testing of these extracts, details of which are not available in the current 
published literature. As part of the optimization of the XTT-assay we investigated the effects 
of the phenol red indicator in RPMI, the use of DMSO as a solvent, and the effects of the 
plant extracts on absorbance measurements.  
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The phenol red indicator contained in RPMI may compromise the optical density 
measurement of the XTT assay. We conducted experiments to determine the effects of both 
colourless RPMI and RPMI containing phenol red indicator on cell suspensions, and the 
overall effects on OD readings.  
 
There was a statistically significant difference in the mean difference pre and post XTT-
incubation i.e.∆, between RPMI with and without phenol red indicator. This is possibly a 
result of the alteration in the colour of the phenol red indicator due to a pH change during the 
course of incubation. Therefore, RPMI containing indicators such as phenol red cannot be 
used in colorimetric cytotoxicity screens and the use of colourless RPMI is essential.  
 
Phenolic plant extracts may require reconstitution in DMSO. Due to potential toxicity of 
DMSO to cells (Weislow et al., 1989), we conducted experiments to determine a 
concentration range of DMSO which would be suitable for both the solubilisation of the plant 
extracts and cell-based cytotoxcity testing. All aqueous plant extracts were reconstituted in 
100% H2O. Phenolic extracts, which required reconstitution in 50-100% DMSO, would be 
diluted in complete RPMI to achieve concentrations of 0.625% DMSO or less prior to use in 
cell based tests. 
       
 Plant extracts are likely to contain various plant enzymes that have the potential to reduce the 
tetrazolium salt to formazan.  Berridge et al. (1993) have shown that XTT may also be 
reduced by NADH and NADPH in the absence of cells and enzymes and that superoxides 
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play a vital role in XTT reduction in the absence of cells. The production of formazan by the 
activity of plant enzymes would mask decreased formazan production due to cytotoxicity and 
provide erroneous results. 
 
We conducted experiments to investigate this hypothesis and found no statistically significant 
effect of plant enzymes on formazan production. 
However, there were significant differences between the baseline OD of the control and each 
of the concentrations of the extract (p<0.05). This finding suggested that the colour of the 
extract is a significant factor in OD calculations in the XTT assay. To account for this, a 
modification was made in the analysis step of the assay. Both pre and post XTT incubation 
OD readings were taken in all subsequent experiments so that pre-incubation OD readings 
could be subtracted from post incubation OD readings. This provided OD readings that solely 
indicated formazan production.  
 
The modified XTT assay protocol was used for the testing of plant extracts, provided by the 
CSIR, and was used to determine EC50 and CC50 values of these extracts prior to further 
investigation of their potential antiviral properties. The percentage protection of each extract 
was calculated at a range of concentrations (Appendix C) and the selectivity indices 





Two established and published XTT assay methods were compared, one using a continuous 
HIV-infected cell line and the other an experimentally infected T-cell line. Both methods 
yielded acceptable selectivity indices for AZT, however, the results were not comparable for 
the plant extracts tested. Furthermore, the absolute percent cell viability and percent 
protection were markedly higher for the chronically infected cells. There are several possible 
explanations for this. The use of different cell lines in the assays is known to yield differing 
selectivity indices (Turk et al, 2002). The experimental infection of the MT4 cells allowed for 
the exact quantification of the number of cells and infectious virions. This would ensure that 
the multiplicity of infection and proportion of infected cells per well were constant. In 
contrast, the chronically infected cells may produce a variable and unknown number of 
virions and the proportion of infected cells per well could not be determined. Experimental 
infection using 100 TCID50 virus ensures that at least 50% of lymphocytes are infected. The 
percent of infected cells in chronically infected lymphocytes cannot be determined and is 
usually low since uninfected cells outgrow the infected cell population. In the XTT 
experiments using chronically infected cells, the uninfected cell population may greatly 
exceed the number of infected cells. Furthermore, healthy uninfected cells may survive 
preferentially compared to infected cells. The uninfected cells will proliferate and be 
measured as viable cells which may be spuriously interpreted as protection of infected cells 
by the test substance. XTT assays performed using experimentally infected cells are far more 
specific than those using chronically infected cells. This needs to be taken into consideration 
when interpreting and comparing selectivity indices reported in the literature. 
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Of the 4 extracts tested, we found two with favorable selectivity indices. These two extracts 
LA5B and MM166A were selected for further testing.  
 
A viral susceptibility assay was developed in order to investigate several plant-derived 
extracts for potential anti-HIV activity. Continuous HIV-infected H9 cells and experimentally 
infected MT4 cells were cultured and exposed to varying concentrations of AZT (used as a 
control) and those plant extracts that demonstrated suitable selectivity indices in XTT assay. 
Cell culture supernatant samples were taken at 3 day intervals for quantification of viral 
replication using both quantitative p24 tests and viral loads.  
The p24 results were inconsistent in chronically infected cells and did not demonstrate the 
expected antiviral efficacy of AZT.  The inconsistency of the p24 measurements could 
possibly be due to the residual cell and virus free p24 antigen that remained on cell surfaces in 
the continuous infected cell line that was used in this study as well as the long half-life of p24. 
In contrast, the tests using experimentally infected cells clearly demonstrated the antiviral 
activity of AZT. The accurate quantification of virus used to infect the cells ensured that the 
virus did not replicate to immeasurable titres and hence avoided the problems seen in the use 
of the chronically infected cells.  
 
Compared to the p24 tests, the viral load results were consistent for both experimentally 
infected cells and chronically infected cells in demonstrating the expected efficacy of AZT.    
This is possibly due to the great linear range of the viral load assay and thus its ability to 
measure extremely high virus concentrations, even in the chronically infected cells where it 
was initially found that viral loads in the culture supernatant greatly exceeded the upper limit 
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of detection of the NASBA viral load techniques (10 x 10
6
 copies per ml). Measurements on 
the NucliSens instrument which exceed the upper limit are indicated by error code “E10” – no 
calibrator. Repeated experiments were required to determine the optimal dilution of the 
supernatant which would permit measurements to be within the dynamic range of the assay. 
The typical dilution factor was 1 000 to 10 000 fold and lysis Buffer was used as a diluent 
when testing the supernatant samples from the chronically infected H9 cultures.  
 
In order to ensure that the infected cells were exposed to the plant extracts through the various 
stages of the virus replication cycle, we used both chronically infected cultures and newly 
infected cultures for all cytotoxicity and antiviral assays.  
We do however acknowledge several limitations to our study. 
The plant extracts used in this study have not been resolved to compounds that can be 
chemically defined. They may contain toxins, inhibitors and stimulators of cell growth that 
could affect the results. Our tests will not yield a positive hit if the extract contains 
compounds that antagonize each other. In this case compounds within the extract that have 
potential anti-HIV activity will be missed. This requires fractionation and “dereplication” and 
further testing of the extract resolved to its individual components. On the other hand, 
screening of crude extracts is still useful and necessary because these extracts may contain 




Only one control (AZT) was used. However, it was not an objective of this study to compare 
compounds with different mechanisms of action. The control was used only to validate the 
experiments and not to compare the efficacy of compounds. 
A limitation of the application of the methods described in this study is that all experiments 
using HIV infected cells must be carried out in specialised BSL III safety facilities. 
Only individuals with skills and expertise in HIV culture and who have been trained to work 
in BSL III facilities may perform such experiments. This limits their capacity for use in high 
throughput screening in laboratories without the appropriate personnel and facilities. 
 
The XTT-based cytotoxicity assay is a rapid, sensitive and cost-effective method of 
determining EC50, CC50  and SI. This test may be adapted for use in a high-throughput 
environment for the screening of potential antiviral compounds. Although 6-day incubations 
provide a sufficient time for the interaction of the test compound with cell cultures, this test 
may be optimised for more rapid cytotoxicity testing. The HIV-infected continuous H9 cells 
and MT4 cells may also be cultured in wells in 96 well plates so that cytotoxicity and antiviral 
testing may be performed concurrently.  
 
Blair et al. (2004) describe a novel antiviral high throughput screening approach called the 
HIV-1 dual reporter assay for the discovery of HIV-1 inhibitors. This assay allows for the 
simultaneous evaluation of cytotoxicities and the potential antiviral activities of compounds in 
a high throughput screening format using gene reporters. This assay can also be used to 
distinguish specific antiviral compounds from non-specific inhibitors or cytotoxic 
compounds. 
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Antiviral high throughput screens are a valuable option for identifying novel anti-HIV agents 
but few are used in practice on an industrial scale due to the labor-intensive process and 
extensive costs. Novel approaches to antiviral screening provide a platform for newer, more 
improved techniques that would enable the effective execution of industrial scale high 
throughput screening. This would allow for greater returns on resource investment when 


















Appendix A. Laboratory Safety 
HIV CULTURE LABORATORY 
 
1. All procedures involving the culture of HIV were carried out in Biosafety Level III 
conditions as specified in the Laboratory Biosafety Manual (published by the World 
Health Organisation) and Biosafety in Microbiological and Biomedical Laboratories 
(published by the Centres for Disease Prevention and Control).  
 
2. These guidelines included, but were not restricted to, the following 
a. Standard Microbiological Practices 
b. Special Practices 
i. The use of needles and sharps was prohibited 
ii. Use of a biological safety cabinet when working with any hazardous 
materials. 
iii. Regular decontamination was performed 
c. Primary Barriers 
i. Gowns made of resistant material were worn when perfoming 
procedures in the HIV culture lab 
ii. Two pairs of long-cuff gloves were worn at all times. 
iii. Plastic face shields were worn at all times 
iv. Surgical caps and shoes were worn at all times  
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d. Secondary Barriers: Laboratory features including 
i. restricted access 
ii. sink for handwashing and an eyewash station 
iii. design of floors, windows and benchtops 
iv. ventilation system 
v. on-site autoclave 
vi. biosafety cabinets 
 
3. All procedures involving the culture of HIV were carried out only in designated areas. 
These areas had access which was restricted to authorized personnel only. 
 
4. All procedures involving the culture of HIV were carried out under the supervision of 
experienced personnel as determined by the Head of Department of Virology. 
 
5. All procedures and protocols relating to accidental exposure to infectious materials were 
made available in the laboratory. 
 
6. All procedures and protocols relating to accidental spillage of infectious or toxic materials 
were made available in the laboratory. 
 




Appendix B. Cell Culture 
1. Complete RPMI: 
• RPMI-1640 media supplemented with L-glutamine containing phenol red indicator 
(Sigma) 
• RPMI-1640, modified media supplemented with L-glutamine without phenol red 
indicator (Sigma) 
• Foetal Calf Serum (Sigma) 
• Antibiotics (Penicillin, Amikacin, Fungizone) (Sigma) 
Complete RPMI (with phenol red) containing 10% foetal calf serum and 0.1% antibiotics was 
used to maintain cell cultures 
Complete RPMI (without phenol red indicator) containing 10% foetal calf serum and 0.1% 
antibiotics was used to make up plant extract, AZT and DMSO dilutions. 












Appendix C. Preparation of Plant Extracts, Drugs, Test Reagents: 
All compounds to be tested were received from CSIR BioProspecting unit in Pretoria 
 
1. HIV-1-18 A 
2. HIV-1-18 B 
3. HIV-1-18 C 












Compounds 18-A, 18-B, 18-B and 18-C were reconstituted in 1:1 DMSO and distilled water. 
Compounds WG-1-94 and WG-1-94B were reconstituted in 100% DMSO. 
All other compounds were reconstituted in 100% sterile, deionised water. 
Compounds were diluted in complete colourless RPMI to yield the following concentrations 
(µg/ml): 0.25, 0.79, 2.5, 7.9, 25, 250 
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AZT: 
Dilutions of AZT were made up to the following concentrations (µM) in complete RPMI-
1640 modified media without phenol red: 
0.0001, 0.001, 0.01, 0.1, 1, 10, 100, 1000 
DMSO: 
DMSO, 99.5% GC (Sigma, USA) was used. 
Dilutions of DMSO were made up to the following concentrations in complete RPMI-1640 
modified media without phenol red : 
6.25%, 0.625% and 0.0625% 
XTT 
XTT/PMS solution was made up according to instructions on the package insert. 
5ml RPMI-1640 modified media without phenol red was added to 5mg XTT/PMS. 











Appendix D. The Trypan Blue Exclusion Method of Cell Counting 
 
20µl of cell suspension and 20µl of 0.1% Trypan blue solution was pipetted into a 500µl 
Eppendorf tube. 
A 1:1 ratio of cell suspension to Trypan blue solution was used, resulting in a dilution factor 
of 2. 
The cell suspension and Trypan blue solution were mixed thoroughly by pipetting up and 
down 10 times. 
The Eppendorf tube was incubated at room temperature for five minutes. 
The Neubauer Haemocytometer was wiped down with 70% Ethanol solution and dried to 
remove any debris. 
10µl of the cell suspension-Trypan blue solution was pipetted into each chamber in the 
haemocytometer by pipetting the volume between the counting slide and the glass coverslip. 
The cytometer was place on the stage of the light microscope and the counting grid viewed 
using the appropriate objective. 
Unstained (clear, refractile) cells in all four outer quadrants of both grids were counted. 
This number was divided by eight to determine the average number of cells in one quadrant. 
The following equation was used to calculate the number of cells per ml of suspension: 
Average number of cells per quadrant x Dilution factor x 10 000 = Number of cells/ml 
The number of cells in a volume of cell suspension was calculated by multiplying the number 




Appendix E. Preparation of cell suspension for the XTT assay: 
 
500µl of cell suspension, of the final cell concentration to be used was added to each labelled 
1ml eppendorf tube.  
The tubes were spun at 1500 rpm for 10 minutes. 
The supernatant was discarded and 500µl of the appropriate concentration of compound, 
made up in complete colourless RPMI, was added. 
The tubes were vortexed gently to reconstitute the cells.  
















Appendix F. Qualitative p24  ELISA 
 
The Murex HIV Antigen mAb is suitable for testing cell culture supernatants (Abbott Murex 
package insert). 
List of Reagents: 
1. Wash Fluid - Concentrated wash fluid contains 45ml concentrated phosphate buffer 
and 0.15% Proclin® as a preservative. 
2. NP40 – contains 10 ml NP40, bovine casein as a stabiliser and bovine aprotinin as a 
protease inhibitor, and 0.05% Proclin®. 
3. Conjugate 1 – contains 0.4ml concentrated biotinylated murine anti-p24 monoclonal 
antibodies, bovine albumin as a stabiliser, heat inactivated mouse serum, and 0.05% 
Proclin®. 
4. Conjugate Diluent 1 – contains 4ml aggregated human IgG in phosphate buffer, heat 
inactivated mouse serum, and 0.05% Proclin®. 
5. Conjugate 2 – contains 0.3ml peroxidase conjugated steptavidin. 
6. Conjugate Diluent 2 – contains 30ml phosphate buffer, bovine casein as a stabiliser 
and bovine aprotinin as a protease inhibitor, and 0.05% Proclin®. 
7. Chromogen solution – contains 0.3ml concentrated tetramethylbenzidine (TMB) 
dissolved in dimethylsulphoxide (DMSO), and 0.02% Thiomersal as preservative. 
8. Substrate buffer – contains 30 ml phosphate citrate buffer and 0.006% hydrogen 
peroxide. 
9. Negative control – contains 2.5ml human serum negative for HIV antigens and 0.1% 
sodium azide as a preservative. 
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10. Matrix – contains 15ml phosphate buffer, bovine casein as a stabiliser and bovine 
aprotinin as a protease inhibitor, and 0.05% Proclin®. 
11. Standard solution – contains 2.5ml recombinant p24 diluted in matrix, bovine casein 
as a stabiliser and bovine aprotinin as a protease inhibitor, and 0.05% Proclin®. 
12. One plate of 96 wells, coated with human anti-HIV polyclonal antibodies with silica 
gel as a drying agent. 
 
Reagent preparation for one 8 well strip:  
 
All reagents were brought to room temperature and prepared as required. 
1. Wash buffer was prepared by adding 2ml concentrated wash fluid to 48ml distilled, 
deionised, sterile water.  
2. Conjugate working solution 1 was prepared by making up 500µl of Diluted Conjugate 
1, (25µl of Conjugate 1 to 475µl of Diluent 1) and adding this to 500µl NP40. 
3. Positive control was made up by adding 60µl standard solution to 60µl matrix. 
4. Conjugate working solution 2 was prepared by diluting Conjugate 2, 100 times, with 
Conjugate diluent 2 by adding 20µl Conjugate 2 to 1.98ml Diluent 2. 







Manual mixing and washing procedures: 
 
1. Mixing using pipette: 
The pipette to be used was set at the appropriate volume so that all liquid could be 
pipetted. 
The entire contents of the well was pipetted up and down for the number of times 
required. 
Pipette tips were changed after each mixing. 
2. Wash procedure 
The first row of wells was aspirated and the contents discarded. 
The entire row of wells was filled with working strength wash fluid. 
This procedure was repeated for every row of wells in turn. 
Each row of wells was left to soak for at least 30 seconds before the wash fluid was 
aspirated and the process repeated 5 times. 
The wells were inverted and tapped dry on blotting paper after each wash. 
  
Method: 
Wash buffer, positive control and conjugate working solutions were prepared as described 
above. 
100µl of conjugate working solution 1 was added to each well, including wells designated for 
positive and negative controls. 100µl of the appropriate cell culture supernatant (sample) was 
added to each well. 100µl of positive control and 100µl of negative control was added to each 
designated control well.  
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The samples/controls were mixed thoroughly with the conjugate working solution 1 in each 
well 5 times, according to the manual mixing method described. 
The strip/s were covered using the provided adhesive plate sealers and incubated for 60 
minutes at 37◦C (Incubation 1). 
 
At the end of Incubation 1, conjugate working solution 2 was prepared as described. 
Each well was then washed 5 times with wash fluid, according to the wash procedure 
described. 
200µl of Conjugate working solution 2 was added to each well. The strips were covered with 
an adhesive plate sealer and incubated for 30 minutes at 37◦C (Incubation 2). 
 
Substrate solution was prepared at the end of incubation 2. 
Each well was washed 5 times according to the wash procedure. 
200µl of substrate solution was added to each well and the strips were incubated for 30 
minutes at room temperature (15◦C to 30◦C). 
 
The reaction was stopped by adding 50µl 1.5M sulphuric acid to each well. The strips were 
tapped gently to ensure mixing. 
The absorbances in the wells were read at 450nm, reference wavelength 620nm, using the   
Tecan Sunrise Microplate Reader. This was done after 5 minutes but within 15 minutes of 
stopping the reactions. 
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Calculation of Results: 
 
N = mean absorbance of Negative controls 
P = mean absorbance of positive controls 
S = absorbance of the sample 
 
The cut-off value was defined as N + 0.050. 
Interpretation of results: 
 
The sample was considered non-reactive if S < N + 0.050 














Appendix G. Quantitative p24 ECLIA  
 
The Roche Cobas HIV antigen kit was used and analysis was performed using the automated 




Calibration was performed once per reagent lot, using the Elecsys HIV Ag Negative calibrator 
(Cal 1) and positive calibrator (Cal 2), and fresh reagents opened within 24 hours prior to 
calibration. 
 
p24 Antigen test principle 
Incubation 1: 
 
• 50µl of sample, a biotinylated monoclonal HIV p24-specific antibody and the 
monoclonal HIV p24 specific antibody labeled with a Ruthenium complex were 







• Streptavadin-coated microparticles were added allowing the complex to be bound to 
the solid phase as a result of interaction between steptavidin and biotin (second 
incubation) 
(Avidin has an extraordinarily high affinity for biotin, 1million times greater then Antigen-




The reaction mixture was aspirated into the measuring cell and the microparticles were 
magnetically captured onto the surface of the electrode. Any unbound reagent and sample was 













The results were determined automatically, using Roche ELECSYS software, by comparing 
the electrochemiluminescent signal from the sample with the cutoff value obtained by 
previous HIV antigen calibration.  The evaluation and calculation of concentration of the 
antigen was carried out by means of a calibration curve that was established using standards 


















Appendix H. Viral Load Assay: 
 
The NASBA NucliSens EasyQ (Biomerieux) was used. 
Lysis: 
 
The lysis buffer was centrifuged for 10 seconds at 1500g. 1000µl of the test sample 
supernatant was added to the buffer. The tube was vortexed and incubated at room 




After incubation, the lysis buffer and sample were centrifuged for 10 seconds at 1500g. 20µl 
of calibrator (made up in elution buffer) was added to the tube. 50µl of vortexed magnetic 
silica solution was added to the tube. The tube was closed and vortexed immediately after 




The tubes were centrifuged for 2 minutes at 1500g. The supernatant was aspirated and 
discarded. 400µl of wash buffer 1 was added to the silica. 450µl of the silica-wash buffer 
solution was transferred to 1.5ml NucliSens Mini Mag tubes and the silica was washed for 30 
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seconds at “STEP 1” on Mini Mag with the Magnet on. With the magnet on, all liquid was 
aspirated and discarded, without removing silica. With the magnet off, 400µl wash buffer 1 
was added and the wash step was repeated. 500µl of Wash buffer 2 was added and the wash 
step repeated. 500µl of wash buffer 3 was added and the solution washed at “STEP 1” for 15 
seconds (Magnet on). All liquid was removed and discarded without disturbing the silica. 
Elution 
 
25µl of Elution buffer was added to each tube. Tubes were incubated for 5 minutes at 60°C in 
thermoshaker at 1400 rpm.Tubes were placed on a magnetic rack and 20µl of sample was 




45µl enzyme diluent was added to the lyophilized enzymes. The enzyme tube was tapped 




90µl primer diluent was added to the lyophilized primers and vortexed until the solutions 
were clear. 10µl primer mix was added to the bottom of each tube containing the eluate. The 
tube strip was placed in a strip holder in the EasyQ incubator and the program initiated. The 
tube caps were placed upside down on the strip holder and 5µl enzyme solution was added to 
108108  
each cap. After the last incubation step, the tubes were closed and the strip centrifuged for 2 
seconds in the Mini-Strip centrifuge. The tubes were transferred to the NucliSens EasyQ 
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